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ABSTRACT OF THESIS 
THE EFFECT OF PITUITARY PARS INTERMEDIA DYSFUNCTION ON 
PROTEIN METABOLISM AND INSULIN SENSITIVITY IN AGED HORSES
Equine pituitary pars intermedia dysfunction (PPID) typically occurs in horses 
older than 15 years of age and is characterized by hair coat abnormalities, muscle atrophy 
and decreased insulin sensitivity. The first objective of this research was to compare the 
rate of whole body protein metabolism and relative abundance of key factors in the 
signaling pathways associated with muscle protein synthesis and protein breakdown in 
response to feeding in Control and PPID horses. No differences (P > 0.05) were seen 
between the PPID and Control groups in whole-body protein metabolism or post-prandial 
activation of the muscle signaling pathways regulating skeletal muscle protein synthesis 
and breakdown. The second objective of this research was to determine if aged horses 
with PPID had reduced insulin sensitivity and alterations in the insulin-mediated 
signaling pathways in the skeletal muscle when compared to non-PPID, aged Control 
horses. Measures of insulin sensitivity and the activation of factors associated with 
protein synthesis and breakdown were similar between the PPID and Control groups (P > 
0.05). Overall, insulin sensitivity and protein metabolism are similar between the PPID 
and Control groups. The studies suggest that abnormalities may exist as a function of 
advanced age rather than PPID status directly. 
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CHAPTER I. 
The literature review 
1.1 INTRODUCTION 
The focus of this review is to examine the literature pertaining to the current 
knowledge of pituitary pars intermedia dysfunction (PPID) in aged horses, specifically as 
it relates to changes in insulin sensitivity and protein metabolism. A summary of the 
prevalence, physiology, and clinical signs associated with PPID will be followed by a 
brief overview of the disease as seen in other species. Next, diagnostic methods and 
treatments for PPID will be discussed.  This will be followed by a synopsis of insulin 
resistance (IR) in the horse including the role of insulin especially as it relates to aged 
horses, current techniques that are being used in the assessment and diagnosis of IR, and 
other conditions that may cause IR will be given. Finally, protein metabolism in the horse 
and other relevant species will be reviewed, including an overview of the factors that 
regulate whole-body protein synthesis and breakdown, the signaling pathways that 
regulate muscle protein synthesis and degradation, a brief overview of the methods used 
to study whole-body and muscle protein metabolism, and the effects of old age on protein 
metabolism. 
1.2 PITUITARY PARS INTERMEDIA DYSFUNCTION 
Pituitary pars intermedia dysfunction (PPID), commonly known as Cushing’s 
disease, is estimated to affect 15% to 30% of horses older than 15 years of age (1, 2). 
However, estimates of its prevalence vary greatly likely due to lack of a set of universally 
accepted diagnostic criteria (3). In an Australian survey of aged horses older than 15 
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years of age, only 1.7% of owners reported having a horse with Equine Cushing’s 
syndrome, but 22% of owners reported that their horse had a change in hair coat, a 
common clinical sign of PPID (4). The onset of PPID usually occurs in horses 18 to 20 
years old and very rarely occurs in horses younger than 10 years of age (5). Despite 
initial reports, it does not appear that the disease has a greater prevalence based on breed 
(6) or sex (7) of the horse.  
1.2.1 Physiology of PPID 
 
The equine pituitary gland is made up of four different regions: pars distalis, pars 
intermedia, pars tuberalis and pars nervosa (Figure 1.1). PPID occurs when an adenoma, 
hypertrophy, or hyperplasia is present on the pars intermedia of the horse’s pituitary 
gland.  
In both the pars distalis and the pars intermedia, pro-opiomelanocortin (POMC) is 
produced by corticotropes and melanotropes, respectively. POMC is further processed to 
yield adrenocorticotropic hormone (ACTH) and β-lipotropin in the pars distalis by 
prohormone convertase 1 (PC1). PC1 is expressed in both corticotropes and 
melanotropes, whereas prohormone convertase 2 (PC2) is only expressed in 
melanotropes. PC2 further cleaves ACTH to α-melanocyte-stimulating hormone (α-
MSH) and corticotropin-like intermediate lobe peptide (CLIP) and cleaves β-lipotropin to 
β-endorphin (β-END), lipotrophin and other small peptides, which are released into the 
bloodstream (Figure 1.2) (8). In a healthy horse, nearly all ACTH is produced in the pars 
distalis; however, in a horse affected by PPID, ACTH is also produced in the pars 
intermedia. Therefore, horses with PPID have increased levels of anti-inflammatory 
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hormones, ACTH and α-MSH. A study of hormonal changes in these horses found that 
ACTH was elevated to a similar level to that of human Cushing’s disease; however, α-
MSH, β-MSH, CLIP and β-END were found to be disproportionately increased (9).  
Dopamine is known to negatively regulate POMC production in the horse by 
inhibiting prohormone convertase activity in the pars intermedia. In horses with PPID, an 
adenoma on the pars intermedia causes dopamine production to decrease leading to an 
increase in POMC-derived peptides. Specifically, a study of pars intermedia tissue found 
that horses with PPID had 8-fold less dopamine concentration than the tissue from aged 
matched controls (10). Additionally, another study found that horses with PPID had a 6-
fold reduction in dopaminergic nerve terminals (11).  Prohoromone convertase is 
inhibited by dopamine and in a study of mice lacking a dopamine receptor PC1 activity 
increased 4-5 fold and PC2 activity increased 2-3 fold (12). Similar changes are believed 
to occur in horses with PPID, since PPID affects dopamine receptors in the pars 
intermedia (9). These changes cause ACTH to be produced at a faster rate than it can be 
cleaved and thus net ACTH production occurs in the pars intermedia, as well as the pars 
distalis.  
In a study of horses injected with a dose of ACTH twice a day for four days, 
ACTH increased plasma cortisol concentrations (13). Additionally, glucose 
concentrations were higher in horses receiving ACTH and a transient increase in insulin 
concentration was seen. Horses with PPID have been shown to have elevated ACTH and 
α-MSH; however an increase in plasma cortisol has not been seen (14, 15). The 
mechanism that would explain this phenomenon is currently unclear. Ultimately, the 
physiological changes that occur as a result of PPID lead to a variety of clinical signs. 
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1.2.2 Clinical Signs 
 
There are many clinical signs associated with PPID and horses can be highly 
variable in their presentation of these clinical signs (Table 1.1). In the early stages of 
PPID, it is possible to have very few or no clinical signs present. The classical sign of 
PPID is hypertrichosis, characterized by a long, curly hair coat that fails to shed, as well, 
delayed shedding, incomplete shedding, and lightening of the hair coat may be present. 
Pathogenesis of this clinical sign is unknown although it has been hypothesized that it 
may occur as a consequence of chronic elevations in MSH peptides due to their known 
role on skin cells (14). Due in part to their long hair coat, horses with PPID have been 
reported to have an increased incidence of hyperhidrosis or excessive sweating. However, 
excessive sweating has been reported even in a cool environment or when the horse is 
body clipped, suggesting that hyperhidrosis may be caused by other factors in addition to 
the long hair coats (5). 
Weight loss and muscle atrophy, primarily in the epaxial and gluteal musculature, 
has also been reported to be associated with PPID (8). Studies of muscle atrophy in 
horses with PPID revealed atrophy of type 2 fibers, sarcoplasmic lipid accumulation, 
increased myofiber size variation, and increased proteolysis which is consistent with 
increased glucocorticoid production as seen in other species (16, 17). Combined with 
muscle loss, horses with PPID may also have abnormal distribution of fat along the crest 
of the neck, over the tail head and behind the eyes. A proposed mechanism of this 
occurrence is that hyperinsulinemia seen in many horses with PPID, may contribute to fat 
deposition by inhibiting lipolysis (5).  
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Insulin resistance is also commonly reported in association with PPID; however, 
it is unclear if it is directly associated with PPID. Two studies have been published 
comparing insulin sensitivity in horses with PPID to younger healthy horses. In both of 
these studies, the horses with PPID were found to be less insulin sensitive than their 
younger counterparts (18, 19), when an intravenous glucose tolerance test and 
euglycemic hyperinsulinemic clamp were used to assess insulin sensitivity. Interestingly, 
a study compared aged (>15 years old) horses with confirmed PPID (positive 
dexamethasone suppression test (DST), hirsutism, and at least one other clinical sign), 
horses with unconfirmed PPID (positive DST, but no hirsutism) and healthy controls 
(negative DST and no hirsutism) (20). The study found that horses with confirmed PPID 
had higher basal levels of plasma glucose and insulin compared to both the unconfirmed 
PPID and control group. It has been suggested that high serum insulin concentrations, 
may be the cause of laminitis in horses (21, 22).  In a study of 40 horses with laminitis, 
70% were found to have PPID as defined by a plasma ACTH concentration greater than 
35 pg/mL. Laminitis is the major clinical complication associated with PPID and is often 
the reason for euthanasia in these horses (7). 
Other clinical signs of PPID include, polyuria and polydipsia, increased 
opportunistic infections, immunosuppression, behavior abnormalities and neurologic 
disease (8). It is important to note that while all of the clinical signs discussed are 
believed to be associated with PPID, the prevalence of very few of the clinical signs have 
been compared with healthy aged horses. In a study of 165 Thoroughbreds looking at the 
ACTH-immunoactive cells of the pars intermedia, 5 out of the 165 mares had an enlarged 
pituitary gland consistent with PPID although none of the horses in this study exhibited 
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clinical signs (23). While many clinical signs have been reported to be associated with 
PPID, the mechanistic cause of most of these signs and the interrelationships between 
these symptoms remains unknown.  
1.2.3 Cushing’s disease in other species 
 
 As previously mentioned, PPID was referred to as Equine Cushing’s disease 
(ECD) or Equine Cushing’s syndrome (ECS) in most scientific literature up until the late 
1990s and these terms are still seen in some of the recent literature, particularly in studies 
published outside of the United States or in Veterinary Medicine journals. Additionally, 
popular press articles, veterinarians, and other people in the equine community, generally 
still refer to PPID as ECD.  
The term Cushing’s syndrome is, by definition, the clinical consequence of 
glucocorticoids acting in excess of physiological requirements. Cushing’s syndrome was 
first described by Harvey Cushing in human patients. He described the clinical features of 
hypercortisolism in people with tumors of the pars distalis (PD), which is the most 
common way people are affected by Cushing’s syndrome (24). Shortly after Harvey 
Cushing first described Cushing’s disease, Pallaske (25) found a similar disease in horses 
that became known as Equine Cushing’s disease (cited by Messer IV and Johnson (26)). 
However, upon further research, it was determined that Cushing’s disease in horses is not 
associated with elevated plasma cortisol (14, 15, 27), which may warrant an alternate 
name for the described syndrome.  
In humans, Cushing’s disease (CD) is rare. The estimated annual incidences of 
human CD are in the range of 1.2 to 2.4 new cases per 1,000,000 (28, 29). Other than 
 7 
 
pituitary tumors, Cushing’s syndrome in humans can also be caused by ectopic syndrome 
(ACTH producing tumors), adrenal adenomas, and carcinomas at 12%, 10%, and 8% of 
cases, respectively (30). Women are more prone to CD than men and may be 3 to 8 times 
more likely to have the disease (30). As well, Cushing’s disease can occur at any age, but 
age of diagnosis peaks from 25 to 50 years (30). Clinical signs associated with the disease 
are truncal obesity where fat is distribution is concentrated in the trunk of the body rather 
than extremities, facial fullness, glucose intolerance, gonadal dysfunction, hirsutism, 
hypertension and muscle weakness. Table 1.2 shows the frequency of clinical signs and 
symptoms associated with human CD as seen in a study by Boscaro et al. (30). 
CD also occurs in other species, such as dogs and very rarely in cats. CD in dogs 
occurs more commonly with 1 to 2 cases per 1,000 dogs diagnosed annually. Although 
diagnosis is much more prevalent, canine CD is very similar in its clinical presentation to 
human CD. Dogs with CD show clinical signs such as abdominal obesity, weight gain, 
fatigue, muscle atrophy and skin changes. It has been proposed that dogs would make a 
good animal model for the human form of CD (31). A comparison of the clinical signs of 
CD as seen in humans, dogs and horses is seen in Table 1.3. The table shows the 
similarities between dogs and human, yet there are few similarities of dogs and humans 
to horses.  
1.2.4 Use of PPID horses as a model for Parkinson’s disease 
 
It has been suggested that horses with PPID may serve as the best animal model 
for Parkinson’s disease (PD) in humans due to the significant similarities between the 
two diseases. PD is a leading cause of neurologic disability in the elderly human 
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population, but research determining the early, initiating factors have been limited due to 
lack of a suitable animal model. PPID and PD are similar in that that they are both 
spontaneous neuroendocrine diseases that affect aged populations (32).  
Additionally, data supports that they are both associated with loss of function 
dopaminergic periventricular neurons. As previously mentioned, a study by Millington et 
al. (10) determined that horses with PPID had eight-fold less dopamine and dopamine 
metabolites in the tissue of the pars intermedia compared with age-matched controls. 
Current PD research suggests that oxidative stress is responsible for inducing damage, 
which may be the contributing factor in neuronal dysfunction and death. Similarly, 
examination of the horse’s pituitary shows increased oxidative stress in the dopaminergic 
neurons of the pars intermedia with age and more severely with PPID (11). The study 
found that horses with PPID had 16 times more 3-nitrotyrosine, a marker of oxidative 
stress, in the pituitary and hypothalamus and aged horses without PPID had 7 times more 
3-nitrotyrosine than young horses.  
Another similarity between PPID and PD is in the neuronal accumulation and 
aggregation of α-synuclein in nerve terminal protein. α-synuclein is a natively unfolded, 
soluble monometic protein that can improperly fold and aggregate in the nerve terminals 
and leukocytes. The accumulation of improperly folded α-synuclein disrupts cellular 
function and will eventually cause cell death (33). The accumulation and aggregation of 
α-synuclein is known to contribute to PD. As well, horses with PPID have been shown to 
have 1.7 times more α-synuclein in the pituitary compared with both healthy aged horses 
and younger controls (33). 
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Despite their apparent similarities, the diseases do differ in several important 
aspects. First, in horses with PPID the adenoma occurs on the pars intermedia, but in 
humans with PD the tumor occurs on the pars distalis. Due to this difference, clinical 
signs of the two diseases are not the same. The second major difference is the lack of 
Lewy body formation in the horse, which is a marker of PD (33).  
Due to the limitations of the model, it is likely the horse model will be best 
utilized in investigating the early, systemic events that lead to PD; however, its usage 
may provide a unique perspective into PD (33). 
1.2.5 Diagnosis of pituitary pars intermedia dysfunction 
 
One of the most reliable indicators of PPID is the presence of hypertrichosis, 
which can positively predict PPID status 90% of the time based on post-mortem 
evaluation (34); however, hypertrichosis is not present in all horses with PPID, 
particularly in early stage cases (5). For this reason, laboratory tests are often used to 
diagnose and confirm PPID status. There are many diagnostic methods and this review 
will focus on three: plasma ACTH concentration, plasma α-MSH concentration and 
dexamethasone suppression test (DST). In addition, there are several other tests that have 
been investigated, including thyroid releasing hormone stimulation test, domperidone 
response test, serum insulin concentration, cortisol circadian rhythm loss, urinary 
cortisol/creatinine ratio and use of magnetic resonance imaging; however, these methods 
are not as well-established (8). Each of these tests can be beneficial to diagnosing PPID; 
however, none are 100% accurate in detecting PPID. Ultimately, post-mortem evaluation 
of the pituitary gland of the horse is the only way to accurately determine PPID status, 
but in clinical practice this is not possible, and therefore, alternate diagnostic tests must 
 10 
 
be performed. It is important to find a test that is highly correlated to the results of post-
mortem evaluation and that can be easily performed in a clinical setting. 
It is known that the adenoma on the pituitary gland of the horse can increase 
ACTH and α-MSH production. When the concentrations of these hormones are 
measured, levels outside of the normal range may indicate PPID status.  Plasma ACTH 
and α-MSH concentrations are determined by taking a single blood sample collected in 
an EDTA tube. PPID diagnosis is based on an ACTH concentration greater than 40-50 
pg/mL (35) and α-MSH concentration greater than 35 pmol/L (36). During the fall 
months, both of these tests can be greatly affected by seasonality, where a natural rise in 
ACTH and α-MSH occurs in the later part of August to mid-September and declines by 
October. α-MSH has the greatest seasonal effects as it increases over 3 times its normal 
range in the fall months from August to October (8). Beech et al. (37) determined that it 
might be necessary to have seasonal reference ranges of 90 pmol/L for the fall months in 
order to accurately diagnose PPID using α-MSH concentration. Additionally, α-MSH is 
not available as a commercial test, so this diagnostic method is not commonly used in 
veterinary practice, although it has proven useful in research settings. ACTH is not as 
seasonally affected as α-MSH (8); however, it can be elevated due to stress, exercise and 
other biological factors (38). 
The dexamethasone suppression test was once considered the goal standard in 
PPID diagnosis. To perform this test, dexamethasone is administered intramuscularly at a 
dose of 0.04 mg/kg and then a blood sample is taken 19-20 hours post dexamethasone 
administration. Diagnosis for PPID is positive if dexamethasone does not suppress blood 
cortisol levels below 1 μg/dL, 19-20 hours later. In healthy aged horses, administering 
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dexamethasone inhibits ACTH release from the pars distalis leading to the suppression of 
cortisol, whereas horses affected by PPID have a decreased ability to suppress cortisol 
since ACTH produced in the pars intermedia is not regulated by glucocorticoid feedback. 
A study by Dybdal et al. (39) found that DST has nearly 100% sensitivity and 100% 
specificity in diagnosing PPID at 19-20 hours post dexamethasone administration when 
evaluated post-mortem. In this case, sensitivity refers to the test’s ability to correctly 
identify a horse with PPID as having PPID and specificity refers to the test’s ability to 
correctly identify a non-affected horse as negative for PPID.  However, later studies 
showed that this test might not be nearly as accurate as initially reported (40). 
A later study compared the three diagnostic tests for specificity and sensitivity 
(40). These tests were evaluated based on post-mortem evaluation of the ratio of the pars 
intermedia to the total pituitary area. During this study, 105 clinically normal horses and 
15 with the clinical signs of PPID were tested for PPID using all 3 diagnostic methods 
and then evaluated post-mortem. Using the ratio pars intermedia area to total pituitary 
area of greater than 0.3 as a positive diagnosis for PPID, sensitivity and specificity in 
non-fall samples for the ACTH test was 71% and 81%, for α-MSH was 63% and 90%, 
and for DST was 65% and 95%, respectively. While all three diagnostic tests were poor 
at correctly identifying non-end stage cases of PPID, the best results (sensitivity=80%, 
specificity=90%) were obtained when both DST and α-MSH were performed and a 
positive result from either test was used to indicate PPID status. The results indicate that 
it may be necessary to use more than one diagnostic test to more accurately diagnose 
PPID. 
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1.2.6 Treatments for PPID 
 
Horses with PPID have additional considerations in both general geriatric 
management as well as pharmaceutical treatment of the disease. For horses with PPID, 
nutrition, parasite control and hoof care have even greater importance. Due to the 
possibility of increased incidence of insulin resistance and laminitis (41), feeds with 
highly soluble carbohydrates should be avoided. Currently, many companies have diets 
formulated specifically for horses with insulin resistance, such as Purina’s WellSolve 
L/S
® 
and Intégri-T
®
. Proactive deworming strategies should be employed for horses with 
PPID due to the increased risk of strongyle infections (36). Additionally, due to their long 
hair coat, horses with PPID may need to be body clipped and provided with ample shade 
during the summer months. 
There are two drugs commonly used to treat PPID: pergolide mesylate and 
cyproheptadine. Pergolide is currently the most commonly used drug due to its ability to 
down regulate POMC derived peptide production by acting as a dopamine D2 receptor 
agonist (8). The drug was originally used to treat Parkinson’s disease, but was voluntarily 
withdrawn from the market in March 2007 (42), due to the 33% increase in vascular heart 
disease seen in human Parkinson’s patients using pergolide, compared with those who 
had never used the drug (43). The withdrawal of human pergolide created a problem for 
veterinarians since there was not a commercially available product containing pergolide 
that was approved for use in horses. Since increased heart lesions have not been reported 
in horses, the Food and Drug Administration (FDA) issued a limited exemption, allowing 
pergolide to be compounded in bulk for veterinary use (42).   
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Reports have demonstrated pergolide’s ability to significantly lower plasma 
ACTH concentrations in horses with PPID (7, 44, 45).  In 40-60% of the horses, ACTH 
was lowered to within normal range (9-35 pg/mL)(44, 45). Horses treated with pergolide 
had ACTH concentrations significantly lower than those horses treated with 
cyproheptadine (7, 44). Further Donaldson et al. (44) found that 85% (17/20) of owners 
with horses on pergolide reported an improvement in the clinical signs associated with 
PPID compared with only 28% (2/7) of owners of the horses treated with cyproheptadine. 
 In September 2011, PRASCEND
® 
Tablets were approved for use in horses with 
PPID (NADA 141-331).  According to Hagyard pharmacy, a major veterinary pharmacy 
in Lexington, KY, the approximate cost of PRASCEND
® 
Tablets is $1.95/per tablet with 
most horses requiring 1 tablet (1 mg of pergolide mesylate per tablet) per day. Due to the 
high cost, it is essential that a horse be correctly diagnosed with PPID. 
Cyproheptadine is a mixed-action drug, which acts as a serotonin antagonist and 
has antihistamine and antimuscarinic effects or the ability to block muscarinic receptors 
(8). Blocking muscarinic recptors helps to increase the level of dopamineragic activity. 
The use of cyproheptadine has limited success when compared to pergolide (7, 44); 
however, it may be beneficial for some equines. It has been suggested that may be useful 
in combination with pergolide when maximal doses of pergolide alone are unsuccessful 
in resolving the clinical signs (8). As well, cyproheptadine’s effectiveness may be 
underestimated because Perkins et al. (45) found that there was no difference in the 
amount that plasma ACTH decreased between horses treated with pergolide and horses 
treated with cyproheptadine. Additionally, the study found that 81% of horses (26/32) 
treated with cyproheptadine and 90% (9/10) treated with pergolide showed improvement 
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of at least one clinical sign. Currently, cyproheptadine is not approved by the FDA for 
use in horses, despite being used in accepted practice. According to Hagyard pharmacy, a 
major veterinary pharmacy in Lexington, KY, the cost of Cyproheptadine 4mg Tablets is 
$104.71 for 1,000 (4mg) tablets. With most horses requiring 0.5 mg/kg BW per day (45), 
a 500 kg horse will require 250 mg per day, at a cost of about $6.50 per day. 
1.3 INSULIN SENSITIVITY IN THE HORSE 
 
 PPID is believed to be associated with decreased insulin sensitivity; however, as 
previously discussed, this relationship has not been well described in the scientific 
literature. Despite the lack of conclusive research, popular press articles and feed 
companies marketing low starch feeds continue to associate PPID with insulin resistance. 
The next section of this literature review will discuss the physiological roles of insulin, 
the concept of insulin resistance, methods used to measure insulin sensitivity in the horse, 
insulin resistance in aged horses and conditions other than PPID that may cause a 
decrease in insulin sensitivity in horses. 
1.3.1 Physiological roles of insulin  
 
Insulin is a dipeptide, containing A and B chains, that are linked by disulphide 
bridges and contains 51 amino acids. Insulin is synthesized as its precursor, proinsulin, by 
the β-cells of the pancreatic islets of Langerhans. Proinsulin is synthesized in the 
ribosomes of the rough endoplasmic reticulum (RER) from mRNA as pre-proinsulin. 
When the signal peptide is removed from pre-proinsulin, proinsulin is formed which is 
 15 
 
transferred from the RER to the Golgi apparatus. Then, enzymes acting outside the Golgi 
apparatus convert proinsulin to insulin and C-peptide (46, 47).  
Insulin secretion from the islet cells into the portal vein is pulsatile and increases 
post-feeding (48). In response to a glucose stimulus, insulin secretion is biphasic meaning 
an initial rapid phase of insulin secretion occurs followed by a less intense, but more 
sustained insulin release (49). Increased levels of glucose induce the first phase of 
glucose-mediated insulin secretion by the release of insulin from the secretory granules of 
the β-cells. The process occurs when glucose entering the β-cell is sensed by glucokinase, 
which phosphorylates glucose to glucose-6-phosphate, generating ATP. Then potassium-
ATP dependent channels close, resulting in membrane depolarization and activation of 
calcium channels. When calcium channels open, intracellular calcium concentrations 
increase leading to a pulsatile secretion of insulin (50). Insulin secretion can also be 
stimulated by other factors such as stimulation of the vagus nerve when food is seen, 
smelled or acutely ingested (51). Peptide hormones such as glucagon- like peptide-1 
(GLP-1) enhance insulin secretion (52) while somatostatin (53) and leptin (54) inhibit 
insulin secretion. Additionally, amino acids, particularly arginine (55), ornithine (56) and 
leucine (57), have been shown to stimulate insulin secretion.  
Upon secretion, insulin interacts with its target cells by binding to specific sites on 
the plasma membrane called receptor sites (58). Insulin acts on cells in the skeletal 
muscle, liver and fat.  Insulin binds to the α subunit of the receptor site causing a 
conformational change, which then allows ATP to bind the β subunit of the receptor site. 
The main insulin receptor in the cell involves tyrosine kinase. This interaction is rapid, 
reversible and triggers a series of internal events that results in the movement of glucose-
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transporter proteins (GLUT4) to the cell surface for glucose uptake. GLUT4 appears the 
major transporter that mediates the insulin response (59). Ultimately, the role of insulin is 
to maintain normal blood glucose levels by facilitating cellular glucose uptake. The major 
sites of insulin mediated glucose uptake include the skeletal muscle and adipose tissues.  
Insulin secretion facilitates glucose uptake by the cells, promotes glycolysis, 
glycogenesis, protein synthesis and ion uptake and inhibits gluconeogenesis, 
glucogenolysis, lipolysis, ketogensis and proteolysis (Figure 1.3) (60). 
In the horse, insulin secretion has a distinct circadian rhythm with maximum 
secretion at 1200h. (61, 62).  The pattern of this rhythm does not appear to be affected by 
PPID status or hay versus concentrate diet as seen in two independent studies (61, 62). 
Additionally, horses show a significant post-feeding rise in plasma insulin concentration 
when fed concentrate, but little increase in insulin concentration when hay is fed (63). 
This is due to increased levels of glucose post-feeding, inducing glucose-mediated insulin 
secretion (47) and dietary amino acids such as arginine and leucine which are known to 
increase insulin secretion (64). Insulin release is decreased during stress and exercise, due 
to the increase in circulating catecholamines, which inhibit insulin secretion (65). In the 
horse, this inhibition occurs at about 50% of VO2max which allows the horse to increase 
gluconeogenesis to maintain blood glucose during exercise (65).  
1.3.2 Insulin Resistance 
 
Insulin resistance (IR) is defined as a condition where normal concentrations of 
insulin produce a subnormal physiologic response (66). It occurs when tissues are not as 
responsive to the actions of insulin, usually due to defects in post receptor insulin 
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signaling. When the tissues no longer elicit the proper response to insulin, the body may 
compensate by increasing insulin secretion. This is known as compensatory 
hyperinsulinaemia and occurs when pancreatic β-cell secretion increases in order to 
maintain normal blood glucose. In humans, the state is maintained until pancreatic 
secretory defects occur and the inability to compensate for decreased insulin sensitivity 
results in increased blood glucose concentrations and type 2 diabetes. In humans, IR is a 
characteristic of type 2 diabetes and is different from the reduction in insulin production 
as seen in type 1 diabetes (67). However, diabetes mellitus in the horse is rare, but it may 
be underdiagnosed in aged horses (68). Horses commonly compensate for decreased 
insulin sensitivity in two ways. First, a horse may compensate by increasing pancreatic β-
cell release and insulin secretion in order to maintain insulin-mediated glucose uptake. 
Alternatively, a horse may increase glucose-mediated glucose uptake (glucose uptake not 
related to insulin, which occurs primarily in the fasted state) in order to decrease the 
concentration of plasma and extracellular glucose (69).  
 In the horse, insulin resistance may occur due to a reduction in the density of 
insulin receptors on the cell surface, malfunction of insulin receptors, defects in internal 
signaling pathways or interference with the translocation or function of GLUT4 proteins 
(70). To distinguish between the different causes of IR, two terms were adopted. The 
first, insulin sensitivity, describes reduced insulin-mediated glucose transport into the 
cell. The second, insulin ineffectiveness, describes a failure of insulin-facilitated 
intracellular glucose utilization (21, 69). These two types of IR may exist separately or 
together depending on the specific case of IR.   
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1.3.3 Conditions associated with insulin resistance in the horse 
 
 As previously discussed, insulin resistance (IR) may be associated with PPID (18, 
19); however, there are many other conditions that are also associated with IR. It has 
been suggested that IR is a factor causing many equine diseases, such as laminitis (71), 
hyperlipidemia (72) and osteochondritis dessicans (OCD) (73). This review will 
specifically discuss the role of IR in laminitis, as well as other factors that affect IR such 
as body condition, activity, diet and age. 
1.3.3.1 Insulin resistance and laminitis 
 
 IR was first associated with laminitis in the 1980’s when two studies found that 
ponies with a history of laminitis were more likely to be insulin resistant that horses with 
no history of laminitis (71, 72). Additionally, more recent studies had similar findings 
using basal proxies, reciprocal of the square root of insulin (RISQI) and modified insulin 
to glucose ratio (MIRG) (74, 75). A further discussion of these proxies can be found in 
Section 1.3.4.2. Analysis of these proxies indicated that the ponies predisposed to 
laminitis had lower insulin sensitivity (RISQI) and higher insulin response (MIRG), 
indicating a compensatory exaggeration of pancreatic β-cell secretion (75). In healthy 
horses, a study demonstrated that laminitis can be induced due to prolonged 
hyperinsulinemia within 48 hours (76). 
 Although, it is well defined that decreased insulin sensitivity and laminitis are 
associated, the cause of this relationship is unknown. Studies have shown that laminitic 
episodes may be able to be predicted using insulin, leptin and measures of generalized 
and localized obesity (77). It was initially suggested that insulin-mediated 
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vasoconstriction may be responsible for causing laminitis (72). More recent hypotheses 
include compromised glucose transport into insulin-dependent cells (21, 78), since 
glucose deprivation has been shown to result in the separation of hoof connective tissue 
(79). While there are many hypotheses of the known relationship between insulin 
resistance and laminitis, none of them have been proven to be the cause of all laminitis 
cases; therefore, it is likely that this is complex relationship that will require further 
research in order to gain a better understanding. 
1.3.3.2 Factors affecting insulin resistance in the horse 
 
IR is affected by many different factors, but it may be particularly affected by age 
(80) body condition (81), activity level (82), and diet (83). 
The relationship between insulin resistance and age is well known; however, the 
cause of this relationship is unclear (84). In human studies, insulin sensitivity was found 
to decrease with age, beginning at 30 years of age and continuing throughout the 
remainder of a person’s lifetime (85).  However, a separate study found that when 
adjusted for increased body weight with age this relationship was no longer significant 
(86). 
 A study found that older horses (27±0.2 yrs) needed nearly 200% and 150% 
more insulin to respond to an oral glucose tolerance test than young (6.8±0.4 yrs) and 
middle-aged  (15.2±0.4 yrs) mares, respectively (87). Additionally, tumor necrosis factor-
α (TNF-α) has been suggested to lead the development of insulin resistance and a study 
of mice found the TNF-α increased with age. This relationship was investigated in the 
horse in a study by Vick et al. (88). The study used the EHC procedure to assess insulin 
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sensitivity in sixty mares and found that insulin sensitivity was negatively correlated with 
body condition score, age, and TNF-α.  The results of this study support previous 
associations that high concentrations of circulating insulin and reduced insulin sensitivity 
occurs in mares with high BCS and these effects may be exacerbated by aging (88). 
The study was hardly the first to associate IR and obesity in horses. Several 
studies have reported decreased insulin sensitivity in obese horses when compared to 
their lean counter parts (81, 83). The decrease in insulin sensitivity seen in obese horses 
seems to improve with weight loss due to both calorie restriction and exercise (81).  
Additionally, fat distribution, such as neck crest adiposity, has been shown to be 
negatively correlated with insulin sensitivity in horses and ponies (89). The relationship 
between insulin resistance and obesity may be due to increased inflammation that occurs 
with obesity. Administration of lipopolysaccharide (LPS) induces an inflammatory 
response with increased concentration of inflammatory cytokines, particularly TNFα. 
Administration of LPS was found to induce insulin resistance within 24 hours in horses 
(90). 
In human studies, exercise has been shown to improve IR even when weight loss 
does not occur (91). Similarly, a study of both lean and obese mares found that exercise 
improved insulin sensitivity without a change in body weight after 7 days of round-pen 
exercise (82). Stewart-Hunt et al. (92) suggested that these findings are due to the effect 
of training on insulin action. They found that GLUT-4 content and glycogen synthase 
activity increased with short-term training and these enhancements were still evident after 
5 days of inactivity. Alternatively, another study found that exercise training alone 
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without dietary restriction did not improve insulin sensitivity in overweight or obese 
horses (93). 
It is also important to understand the relationship between diet and IR. A study by 
Hoffman et al. (83) showed that healthy horses adapted to sweet feeds that are high in 
non-structural carbohydrates, such as starch and sugars, had decreased insulin sensitivity. 
Additionally, the study results suggested that the effect of non-structural carbohydrates 
may be magnified in horses with preexisting IR. A second study found that weanlings 
adapted to a sugar and starch diet had decreased insulin sensitivity when compared to 
weanlings on a fat and fiber diet; however, this decrease in insulin sensitivity appeared to 
be compensated for with increased β-cell secretion of insulin (94). 
Overall, there are many factors that can affect insulin sensitivity in the horse and 
many of these factors are interrelated. It is important to understand these risk factors in 
order to assess a horse’s risk for insulin resistance. 
1.3.4 Methods used to measure insulin sensitivity  
 
 There are many methods used to measure insulin sensitivity, each with its own 
advantages and disadvantages. Depending on the specific situation, it may be necessary 
to use one or a combination of these methods in order to quantify insulin sensitivity in the 
horse.  While there are many methods that can be employed, this review will focus on 
five methods including, basal hyperglycemia and hyperinsulinemia, proxies and surrogate 
testing, glucose tolerance test, minimal model of glucose-insulin dynamics and the 
euglycemic-hyperinsulinemic clamp (EHC) technique. 
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1.3.4.1 Basal hyperglycemia and hyperinsulinemia 
 
 Measurement of fasting plasma glucose and insulin concentrations is a simple 
screening test that involves a single blood sample. The technique may be useful in 
obtaining some information about insulin sensitivity with minimal effort on the part of 
the person testing. Measuring plasma glucose is not extremely effective due to its 
inability to differentiate between inadequate secretion of insulin by pancreatic β-cells or a 
decrease in insulin sensitivity of tissues (95). Conversely, basal hyperinsulinemia was 
once considered a certain sign of IR; however, upon further research new methods were 
developed which gave a better indication of the insulin sensitivity of the horse.  Basal 
hyperinsulinemia only occurs when insulin insensitivity of the tissues is overcompensated 
for by increased insulin secretion; however, decreased insulin sensitivity caused by 
decreased secretion of insulin will not be detected (95). Therefore, basal 
hyperinsulinemia may be useful to detect some cases of IR, but not others. When 
measuring plasma glucose and insulin concentrations, the cutoff value for hyperglycemia 
and hyperinsulinemia has not been well defined. The cutoff values of 5.5 mmol/L and 36 
µIU/mL have been suggested for hyperglycaemia and hyperinsulinaemia in adult horses, 
respectively (20). 
1.3.4.2 Proxies and surrogate tests 
 
 Several simple tests have been developed to determine IR in humans. These 
screening tests are based on equations that use fasting plasma glucose and insulin 
concentration. In human medicine, there are many screening tests used, including 
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HOMA-IS, QUICKI, RISQI and MIRG. Table 1.4 shows the full names and equations 
used to calculate these proxies.  
While commonly used in humans, the use of these proxies has only been recently 
investigated in the horse. A study by Treiber et al. (96) compared the use of different 
proxies to the minimal model of glucose and insulin dynamics determined using a 
frequently sampled intravenous glucose tolerance test, a much more intensive procedure 
known to accurately measure insulin sensitivity. The study found that RISQI (r=0.774) 
was the best predictor of insulin sensitivity and MIRG (r= 0.754) was the most accurate 
predictor of β-cell responsiveness. The combined use of these proxies allows for the 
assessment of insulin response and compensatory insulin secretion. The authors proposed 
that the use of these may be useful in research on large populations or in clinical 
situations requiring convenient and cost-effective evaluations of insulin resistance where 
a dynamic test cannot be performed and nonspecific indicators, such as basal 
hyperinsulinemia, do not characterize cause of insulin resistance (96). 
1.3.4.3 Glucose tolerance testing 
 
 The glucose tolerance test measures the plasma glucose response to an oral or IV 
administration of a specified dose of glucose using the time integral or area under the 
curve. This test was originally developed to classify carbohydrate tolerance in humans. 
However, because plasma glucose and insulin responses during this test may reflect the 
ability of pancreatic β-cells to secrete insulin and tissues sensitivity to insulin, the test has 
also been used to evaluate IR (97). 
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 Recently, the oral sugar test was developed to test horses in the field. The test 
works by orally administering corn syrup using a syringe at a dose of 15 mL per 100 kg 
BW. Then, a single blood sample is taken 60-90 minutes later. An insulin concentration 
greater than 60 µU/mL at this time is indicative of insulin resistance in the horse (98). 
The glucose tolerance test may be useful in horses since it is does not require as much 
labor and time as some of the other diagnostic methods for IR. The major limitation of 
the test is that glucose intolerance does not necessarily coexist with IR. The test cannot 
distinguish between factors, such as insulin secretion or insulin sensitivity, which may 
cause failure of glucose homeostasis (99). Despite the limitations of this method, it has 
been considered evidence of IR in several studies of horses including horses with PPID 
(18), fasted ponies (100), mature obese ponies (101) and laminitic ponies (72). 
1.3.4.4 Minimal model analysis of the frequently sampled intravenous glucose tolerance 
test 
 
 The minimal model of glucose-insulin dynamics is a dynamic test of insulin 
resistance, which divides glucose disposal into two parts, glucose and insulin-mediated 
disposal. The model describes the glucose time curve as 2 differential equations. The first 
represents glucose-mediated glucose disposal by use of as single rate constant and the 
second represents insulin mediated glucose disposal by use of a rate constant and insulin 
sensitivity (95). 
An application of the minimal model is in the modified frequent sampling i.v. 
glucose tolerance test (FSIGT). To perform the technique, a bolus of glucose is 
administered intravenously. Then 20 minutes after the glucose bolus, an insulin bolus is 
administered at a dose, which would accelerate glucose disposal, but not promote 
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hypoglycemia. The technique lasts 3-4 hours and blood samples are taken frequently  (1-
3 minutes between samples) particularly in the first 30 minutes and then the time between 
samples increases to approximately 30 minutes in the last 1-2 hours of the procedure 
(83). 
 Plasma insulin and glucose concentrations during sampling are determined and 
used to calculate four output measures. Glucose effectiveness (Sg), insulin sensitivity 
(Si), acute insulin response to glucose (AIRg) and the disposition index (DI) must be 
calculated using computer software. A diagram of the minimal model used to interpret 
the modified FSIGT is shown in Figure 1.4. To define these terms, glucose effectiveness 
(Sg) refers to the capacity of glucose to mediate its own disposal independent of a change 
in plasma insulin and insulin sensitivity (Si) refers to the capacity of insulin to promote 
its own disposal. Acute insulin response to glucose (AIRg) quantifies the endogenous 
insulin secretion in response to the glucose dose. Disposition index (DI) describes β-cell 
responsiveness and accounts for the influence of endogenous insulin secretion (AIRg) 
and Si (83). 
The frequent sampling makes this a labor-intensive procedure requiring many 
trained personnel to properly perform the technique. Additionally, concerns have been 
raised about the calculation of glucose-mediated disposal using a single-rate constant 
which may not always adequately describe the glucose component of the model (102).  
1.3.4.5 Euglycemic hyperinsulinemic clamp technique  
 
 The euglycemic hyperinsulinemic clamp (EHC) technique was introduced in 
human medicine by DeFronzo et al. (103) and gained initial acceptance as the best 
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method to quantify IR. Later, this technique was applied for use in the horse (82). To 
perform the technique, the horse must be outfitted with two catheters, one to infuse 
glucose and insulin and the second to obtain blood samples. The method replicates a state 
of hyperinsulinemia by infusing insulin at a constant rate that is based on the horse’s 
body weight. During the insulin infusion, frequent blood samples are taken and analyzed 
for glucose concentration using an automated analyzer. Then the rate of glucose infusion 
is subsequently adjusted in order to maintain euglycemia. When the rate of glucose 
infusion reaches plateau the rate of glucose infusion is assumed to equal the rate of 
glucose disposal (104). 
 The EHC technique was found to be more repeatable than the minimal model 
analysis of the FSIGT for determining insulin sensitivity in the horse (105). This may 
make it more desirable for studies where the same horse is studied multiple times. 
Additionally, the EHC technique is advantageous for situations where the horse needs to 
be in an insulin-stimulated state at the end of the procedure as in the case of a muscle 
biopsy. While the EHC is a well-accepted technique, the method does not come without 
some disadvantages. It is labor intensive, as many samples need to be collected in order 
to maintain stable glucose concentrations. Additionally, the technique determines the 
sensitivity of tissues to insulin; however, it does not account for the sensitivity of β-cells 
to glucose. It has also been argued that the conditions of the EHC are non-physiologic, 
since the measured glucose disposal rate corresponds to an abnormally high insulin level 
(102). However, this can be avoided by using lower rates of insulin infusion that create a 
more physiologic state as seen in several studies (82, 88). 
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1.4 PROTEIN METABOLISM IN THE HORSE 
 
 Protein metabolism refers to the sum of all biochemical processes required for 
protein synthesis and protein breakdown. This review will cover protein synthesis as it is 
regulated through the mTOR pathway, suppression of the mTOR pathway by myostatin 
and  protein breakdown as it is regulated through the ubiquitin-proteasome pathways and 
factors that interact with this pathways of protein breakdown including the FoxO family 
and NF-κB. This will be followed by a review of isotope infusion methodology to study 
protein metabolism and the effect of aging on whole body protein metabolism. 
1.4.1 Protein synthesis and the mTOR pathway 
 
The process of protein synthesis occurs when the nucleotides in mRNA are 
decoded into amino acids that are linked via peptide bonds in order to form a new 
protein. The process of protein synthesis can be divided into three stages: initiation, 
elongation, and termination.  A number of the components involved in initiation and 
elongation stages of translation are controlled by the mechanistic, formally known as 
mammalian, target of rapamycin (mTOR) pathway (106). The mTOR signaling pathway 
was initially discovered in 1991 in yeast cells (107) and has been extensively studied in 
the skeletal muscle of humans (108, 109), rodents (110, 111), piglets (112-114) and to a 
lesser extent in the horse (115, 116). The mTOR pathway has been the subject of many 
recent reviews (106, 117, 118). Briefly, mTOR is phosphorylated and activated by a 
number of upstream pathways, which are activated by factors such as insulin, amino 
acids and exercise. Upon activation, mTOR affects a series of downstream regulators 
leading to an increase in protein synthesis. A simplified schematic of this pathway can be 
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seen in Figure 1.5. The effects of mTOR on protein synthesis will be further discussed in 
this review, including upstream pathway activators and downstream effectors. The ability 
of myostatin to suppress protein synthesis will be reviewed and this will be followed by a 
summary of what is currently known about mTOR signaling in the skeletal muscle of 
horses. 
1.4.1.1 Activation of mTOR 
 
Insulin is a major activator of the mTOR pathway through Akt, which is also 
known as protein kinase B (PKB). In this interaction, a subunit activated by insulin 
phosphorylates Akt at the Ser
473 
and Thr
308 
phosphorylation sites, activating Akt (119). 
Activation of Akt leads to activation of mTOR by inhibiting negative regulators of 
mTOR known as 40 kDa protein rich Akt substrate (PRAS40) and tuberous sclerosis 2 
(TSC2) (120, 121).  Akt is also responsible for phosphorylation of transcription factors, 
forkheadbox protein O1 (FoxO1) and forkheadbox protein O3 (FoxO3) (111, 122). These 
factors are involved in regulation of protein breakdown and activate the expression of 
genes regulating apoptosis. A further discussion of this regulation can be found in Section 
1.3.2. Additionally, activation of Akt results in the movement of glucose transporter 4 
(GLUT4) to the cell membrane resulting in the transport of glucose in the cell (123). 
Movement of glucose into the cells does not directly influence mTOR signaling 
(124); however, cellular energy is needed to drive mTOR signaling. ATP is produced by 
glucose as a product of glycolysis. When levels of ATP in the cell are high, AMP 
activated protein kinase (AMPK) activity is inhibited (125). Similarly, when levels of 
ATP are low and levels of AMP are high, AMPK becomes active. Ultimately, through a 
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series of phosphorylations AMPK inhibits mTOR by phosphorylating regulatory-
associated protein of mTOR (RAPTOR) (110, 126). Therefore, any physiological state, 
which effects glucose metabolism, will in turn affect mTOR (127) .  
Intracellular amino acids stimulate mTOR signaling through a system of amino 
acid transporters that move the amino acids from the blood to the muscle. Particularly, 
arginine and leucine have been identified as key amino acids that stimulate mTOR (128, 
129). Studies have demonstrated the ability of leucine enriched mixture to decrease 
phosphorylation of eEF2, which promotes elongation and stimulated muscle protein 
fractional synthesis rates (130). It is unclear how amino acids stimulate mTOR activation; 
however, mitogen-activated protein 4 kinase kinase kinase (MAP4K3), PI3K catalytic 
subunit type 3 (VPS34) and Rag GTPases have been identified as potential mediators. 
When MAP4K3 is stimulated by amino acids it is believed to activate S6K1 independent 
of mTOR (131). VPS34 may be the primary modulator of mTOR signaling in response to 
amino acids and it has been suggested that VPS34 is required for leucine stimulation of 
S6K1 (132). The Rag GTPases become activated in the presence of amino acids and 
interact with RAPTOR resulting in mTOR relocation onto the surface of endosomes and 
lysosomes.  This movement may enable allow mTOR to interact with Ras homolog 
enriched in brain (Rheb) leading to mTOR activation (133). Ultimately, amino acids 
stimulate protein synthesis specifically at the points of translation and elongation.  
Exercise has been shown to increase protein turnover leading to an increase in 
muscle fiber size; however, during aerobic exercise mTOR signaling is suppressed. 
Several mechanisms have been proposed for the decrease in mTOR signaling during 
aerobic exercise. One way that exercise suppresses mTOR signaling is by increasing the 
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expression of regulated in development and DNA damage response 1 (REDD1), a 
hypoxia induced gene. REDD1 activates TSC1/2 complex, leading to a reduction in 
mTOR signaling (134). Other proposed mechanisms include suppression of mTOR by 
AMPK (135) and suppression of mTOR due to a decrease in eEF2 phosphorylation (136). 
Some exercise increases skeletal muscle contractile activity increasing the mechanical 
stimulation of muscle fibers. Mechanical stimulation increases the activity of mTOR, 
thus increasing protein synthesis and leading to an enlargement in muscle fibers (137). 
Following short-term resistance exercise in rodents, an immediate increase in mTOR 
signaling factors was seen (138), particularly in the downstream effectors leading to 
protein synthesis. mTOR signaling is suppressed during exercise and then increased to 
during the recovery period leading to muscle hypertrophy (138). 
1.4.1.2 Downstream regulators of mTOR 
 
Following the activation of mTOR, a series of cell signaling events lead to the 
initiation of mRNA translation into protein. When mTOR is activated, 70kDa S6 kinase 1 
(S6K1) and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4EBP1) become 
phosphorylated through RAPTOR (139).  
Once activated, S6K1 phosphorylates several downstream proteins required for 
RNA processing and mRNA translation initiation, including ribosomal protein S6 (rps6) 
and eIF4B. rps6 is an important factor known to aid in the determination of cell growth 
by controlling cell size and cell division (140). rps6 knockout mouse embryo fibroblasts 
have been shown to have an accelerated cell division due to a shortened G1 phase (141). 
S6K1 and rps6 activation was initially thought to be important to up regulate translational 
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capacity by enhancing the translation of components required for protein synthesis; 
however this theory has been disproven (142, 143). When phosphorylated, eIF4B is 
required for ribosomal recruitment to mRNA through a ribosomal subunit pre-initiation 
complex (144). Ultimately, S6K1 plays an important role in the regulation of cell growth, 
cell cycle progression, and cell proliferation (145). 
mTOR activation leads to the phosphorylation of 4EBP1, a regulator of the eIF4F 
complex that is required in the initiation of cap-dependent mRNA translation (146). 
When 4EBP1 is phosphorylated, it separates from eIF4E. This allows eIF4E to associate 
with eIF4G, which leads to the formation of the initiation complex, eIF4F. Once this 
complex is formed, initiation is followed by elongation and thus protein synthesis occurs 
(147).  
1.4.1.3 mTOR signaling in the skeletal muscle of horses. 
 
 The molecular signaling pathway that regulates protein synthesis has been 
extensively studied in cell culture (107) , rodents (110, 111) , neonatal piglets (112-114)  
and humans (108, 109) ; however, only few recent studies have looked at mTOR 
signaling in the horse (115, 116). A study of mTOR in the horse demonstrated that the 
anabolic stimulus of meal consumption increased mTOR signaling, which agrees with the 
results of previous studies in other species (115). When the post-feeding response of 
yearlings, 2 year olds and mature horses were compared, the greatest increase in mTOR 
signaling factors occurred in the yearling horses (116). Another study investigated the 
effect of repeated muscle biopsies over a 5 days period on mTOR signaling.  It was 
determined that mTOR signaling, specifically phosphorylation of S6K1, rpS6 and 
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4EBP1, is increased with repeated muscle biopsies. However, phosphorylation of these 
mTOR signaling factors was not altered by repeated biopsies when an oral anti-
inflammatory was administered (148). Additionally, mTOR signaling does not appear to 
be affected by muscle biopsy depth in horses (149). 
1.4.1.4 Myostatin 
 
 Myostatin, also known as growth and differentiation factor 8 is a member of the 
transforming growth factor-β superfamily and a negative regulator of skeletal muscle 
mass. Disrupted myostatin gene expression is associated with increased skeletal muscle 
mass resulting from muscle fiber hyperplasia and hypertrophy (150). Studies have 
demonstrated that recombinant myostatin protein inhibits muscle cell proliferation and 
protein synthesis in vitro (151). Additionally, dexamethasone administration, which has 
been shown to decrease skeletal muscle mass (152), leads to increased myostatin 
expression in rats (153). Further, when dexamethasone was administered to mice with the 
myostatin gene deleted, skeletal muscle atrophy did not occur (154). 
 Myostatin leads to muscle atrophy through phosphorylation of Smad2 and Smad3, 
which block muscle differentiation. Smad 2 and Smad3 activation are both required in 
order for myostatin to inhibit protein synthesis (155). It has been demonstrated that 
myostatin inhibits the activation of Akt, TORC1 and p70 leading to decreased protein 
synthesis and muscle loss (155). Interestingly, although inactivation of Akt usually leads 
to upregulation of MuRF1 and atrogin-1, the study found MuRF1 and atrogin-1 
expression were downregulated by myostatin (155). Therefore, the authors hypothesized 
that myostatin can block the induction of muscle’s differentiation program (155).  
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1.4.2 Protein breakdown 
 
 The degradation of protein is important for the control of growth and in normal 
metabolism. Protein breakdown allows for protein turnover and provides quality control 
by selectively eliminating abnormally folded proteins. However, when the rate of protein 
breakdown exceeds the rate of protein synthesis, muscle atrophy occurs (156). Muscle 
atrophy is defined as a decrease in muscle mass including a decrease in size and number 
of skeletal muscle fibers.  The pathways regulating protein synthesis and breakdown are 
highly interrelated. When protein synthesis occurs, it inhibits factors associated with 
muscle atrophy and when atrophy occurs protein synthesis pathways are inhibited (157). 
A simplified schematic of the proposed relationship between protein synthesis and 
breakdown can be seen in Figure 1.6. Muscle protein breakdown is regulated 
predominantly through the ubiquitin-proteasome pathway, as well as through the 
lysosomal and calpain pathways (158). These pathways associated with protein 
breakdown may be altered by various physiologic states such as aging (111, 159), insulin 
resistance (157), and during postprandial and post-absorptive states (160). This review 
will specifically cover the ubiquitin-proteasome pathways and factors that interact with 
this pathways of protein breakdown, including the FoxO family and NF-κB.  
1.4.2.1 Ubiquitin-proteasome pathway 
 
The ubiquitin proteasome pathway is responsible for the degradation of most of 
the skeletal muscle proteins (158). Ubiquitin is a small highly conserved regulatory 
protein that, when added to a protein substrate, regulates signaling processes associated 
with muscle atrophy. Three unique enzymatic components are required in this signaling 
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process, including E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and 
E3 ubiquitin-ligating enzyme (161). Currently, several hundred distinct E3s have been 
identified and it is likely that each of these ubiquitin-ligating enzymes regulates 
ubiquitination of a specific set of substrates (162). Therefore, the regulation of 
ubiquitination can be part of a coordinated signaling pathway, analogous to 
phosphorylation. Rates of protein degradation increase through the ubiquitin proteasome 
pathways protein synthesis is blocked (163) and the amount of polyubiquitin conjugation 
compared to total protein increase (164). Additionally, mRNA levels of genes that encode 
ubiquitin-conjugating enzymes that are part of the ubiquitin pathway were found to 
increase during atrophy (165). 
1.4.2.2 MuRF1 and atrogin-1 
 
The genes for two E3 ubiquitin ligases have been shown to increase in expression 
in multiple models of skeletal muscle atrophy. These genes are known as muscle-RING 
(really interesting new gene)-finger protein 1 (MuRF1) and muscle atrophy F-box 
(MAFbx; also known as atrogin-1) (166).  Consistent increases in the gene expression of 
these two factors have been observed in models of skeletal muscle atrophy including 
diabetes, cancer, and adrenal failure (167). MuRF1 encodes a protein that contains three 
domains required for ubiquitin-ligase activity (168) and formation of heterodimers 
between MuRF1 and MuRF2 (169). MuRF1 has been demonstrated to be in the nucleus 
and may have a role in both regulation of myofibril assembly and muscle gene expression 
(170). Atrogin-1 contains three domains including an F-box domain. An experiment in 
mice revealed that when MuRF1 and atrogin-1 knockout mice were compared to their 
littermates, all mice appeared phenotypically normal. However, when subject to 
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physiologic conditions that would usually cause muscle atrophy, significantly less muscle 
mass was lost in the knockout animals (166). The requirement of MuRF1 and atrogin-1 
for skeletal muscle atrophy makes them potential targets for drug discoveries since they 
are required for muscle atrophy, are expressed specifically in muscle cells, and do not 
seem to be required for normal muscle growth and function (171).  
1.4.2.3 FoxO family 
 
The FoxO family is an important factor in the ubiquitin proteasome pathway of 
protein breakdown that when activated leads to protein breakdown through increasing the 
expression of atrogin-1 (172). Members of the forkhead box containing protein, O sub-
family or FoxO family of transcription factors have been shown to play a variety of roles 
in the cellular processes including longevity, metabolism and reproduction and regulation 
of gene transcription (173). There are 3 primary members of the FoxO family: FoxO1, 
FoxO3a and FoxO4. FoxO1 has been suggested to have a crucial role in vascular 
formation (174). Both FoxO3a and FoxO4 null mice were viable and did not appear 
phenotypically different from their littermates. However, female FoxO3a null mice were 
infertile and had abnormal ovarian follicular development (174). Interesting, the FoxO3a 
and FoxO1a genotype has been found to be strongly associated with longevity in humans 
(175, 176). It is believed that the expression of the FoxO genes may help explain the 
increased longevity seen in females (176).  
Akt regulates the FoxO family through phosphoinositide-3-kinase (PI3K) 
signaling.  Thus, when Akt/PI3K is phosphorylated, FoxO is subsequently 
phosphorylated and inactivated leading to decreased expression of atrogin-1 and 
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ultimately a decrease in muscle atrophy (172). However, a study showed that FoxO3 
could also be regulated in the absence of phosphorylated Akt through interaction with 
IKKβ, a major catalytic subunit of IκB kinase complex (IKK). When this interaction 
occurs, IKK phosphoryates FoxO3a, inhibiting it, and causes proteoloysis of FoxO3a via 
the ubiquitination-dependent proteasome pathway. Downregulation of FoxO3a by IKK 
can induce cell proliferation and tumorigenesis (177). Ultimately, the FoxO family of 
transcription factors play an important role in upregulating factors associated with muscle 
atrophy. 
1.4.2.4 NF-κB  
 
NF-κB is stimulated by inflammatory cytokines, particularly TNF-α, and leads to 
increased expression of MuRF-1 (178, 179). In cells of the immune and inflammatory 
systems, NF-κB was demonstrated to be an integration site for pro-inflammatory signals 
and a regulator of inflammatory target genes (180). NF-κB activation increases the 
production of cytokines and begins a positive feedback loop (178). Activation and 
phosphorylation of NF-κB is controlled by phosphorylation of IKK (181). When the NF-
κB is activated, significant atrophy is induced due to upregulation of MuRF1, but not 
atrogin-1 (179). However, without the presence of MuRF-1, activation of NF-κB did not 
induce significant atrophy. Thus, it appears transcriptional activation of MuRF1 by NF-
κB is a necessary step in NF-κB induced atrophy and a linear signaling pathway had been 
proposed between IKK, NF-κB, and MuRF1 (Figure 1.6). Alternatively, atrogin-1 is 
stimulated by p38, a mitogen-activated protein kinase (MAPK), not NF-κB. A study 
determined that TNFα stimulates atrogin-1 expression and atrogin-1 could not be 
upregulated when p38 was blocked (182). p38 MAPK has been identified as a potential 
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regulator of muscle catabolism and activity of p38 is increased in aging (183) and type II 
diabetes (184). A study of endotoxin induced laminitis in horses found that 
phosphorylation and thus activation of p38 peaked at 12 h of LPS infusion (185).  
1.4.3 Introduction to whole body protein metabolism 
 The regulation of protein synthesis and breakdown is important to overall 
metabolic and physiological homeostasis. The overall sum of protein synthesis and 
breakdown can be measured and expressed as whole-body protein metabolism. Whole-
body protein metabolism is affected by factors such as diet (186), age and exercise (187) . 
These changes can be measured using isotope infusion techniques to measure rates of 
whole-body protein synthesis and breakdown and muscle protein synthesis. This section 
of the literature review will focus specifically on the isotope infusion methodology and 
the effect of aging on whole body protein metabolism. 
1.4.3.1 Isotope methodology 
 
Whole body protein metabolism can be studied by infusing a stable amino acid 
isotope, such as labeled leucine, glycine and phenylalanine. In studies of the horse, [1-
13
C]phenylalanine has been used for isotope infusion (188, 189). An estimation of whole-
body protein synthesis is based on the principle that phenylalanine flux is equal to the 
rate phenylalanine enters and exits the free amino acid pool and is calculated from the 
dilution of labeled to unlabeled phenylalanine in the plasma. By measuring phenylalanine 
flux and rates of phenylalanine oxidation to carbon dioxide (CO2) during isotope 
infusion, rates of whole body synthesis and breakdown can be measured using a 
stochastic approach (Figure 1.7) (190) 
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The measurement of whole body protein synthesis is based on the ability to 
calculate the amount of labeled phenylalanine isotope to unlabeled phenylalanine in the 
plasma free amino acid pool. Urschel et al. (188) used the formulas established in human 
studies (191) and applied these equations for use in the horse. Entering the pool, dietary 
intake (I) refers to the estimated amount of phenylalanine coming from the diet. For the 
horse, I was estimated as the dietary phenylalanine multiplied by 0.5 in order to account 
for prececal phenylalanine digestibility and the dietary phenylalanine that is extracted 
during the first-pass splanchnic metabolism (188).   Also entering the pool, the release of 
phenylalanine from protein breakdown (B) is measured by finding the difference between 
phenylalanine flux (Q) and I.  
Leaving the pool, phenylalanine oxidation to CO2 (E), known as oxidative 
disposal, is measured by collecting breath samples. Also leaving the pool, phenylalanine 
used in protein synthesis (Z) is measured by subtracting phenylalanine oxidation (E) from 
flux (Q). Conversion to other metabolites (M) is assumed to be negligible as long as 
tyrosine intake is equal between all treatment groups and in excess of estimated 
requirements. The sum of these two parts (Z+M) is known as non-oxidative disposal. 
Therefore, phenylalanine flux (Q) is assumed to equal the rate phenylalanine enters (I+B) 
and exits (E+Z+M) the free amino acid pool.  
1.4.3.2 Effect of aging on whole body protein synthesis 
 
 Studies of the effect of age on protein metabolism in humans have provided 
largely mixed results. Some studies have shown that whole body protein metabolism 
decreases with age (192), while others have shown no difference (187). Discrepancies 
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between human studies may be due to differences in body composition and activity that 
usually occur with increased age.  
 Short et al. (187) found that the rates of whole body muscle protein synthesis 
declined with age. Although there was a reduction in the amount of fat-free mass that 
occurred with age, when the rates of whole body protein synthesis were adjusted for fat 
free mass, a negative correlation was still found between age and whole body protein 
turnover. Additionally, the study suggested that some of the negative effects of aging on 
whole body protein synthesis could be reversed with the addition of an exercise regimen. 
Conversely, a study by Chevalier et al. (192), found that aging did not alter whole-body 
insulin sensitivity and protein anabolic responses. The authors hypothesized that this was 
due to similar muscle mass index and level of physical activity between the elderly and 
young group. The study suggests that increased muscle atrophy that occurs with age may 
be the result of increased adiposity and inactivity rather than from chronological age. 
Ultimately, the relationship between aging and whole body protein metabolism is 
complex and may be influenced by a number of factors including diet, body composition 
and activity level. 
1.4.3.3 Effect of aging on protein digestibility 
  
Studies in humans have found that protein availability may decrease with age 
(193). In human studies of young men, a slowly digested dietary protein (casein) lead to 
greater protein gain than a quickly digested protein (whey); however, a subsequent study 
showed that elderly males may benefit from a quickly digested protein compared with a 
slowly digested protein in order to limit protein loss (193, 194). In horses, there is some 
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evidence to support that protein digestion may decrease with advanced age. In an early 
study, apparent crude protein digestion was reduced in aged horses (~25 yrs) when 
compared with younger horses (~2 yrs) (195); however, in later studies of aged horses, 
protein digestion was within the normal range of apparent protein digestion reported for 
younger horses (196). Despite some evidence that protein requirements are different in 
aged horses when compared to younger horses, the current edition of the NRC does not 
make separate requirements due to inadequate support in the literature. 
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1.5 TABLES: 
 
Table 1.1: Reported prevalence of clinical signs of PPID in horses and ponies.  
Clinical Sign McFarlane 
et al. (11) 
McGowan 
et al. (61) 
Donaldson 
et al. (44) 
Schott et 
al. (7) 
Couëtil  
et al. 
(35) 
Hillyer  
et al. (27) 
Total 
Hirsutism 58%  
(7/12) 
100% 
(20/20) 
59% 
(16/27) 
83% 
(64/77) 
95% 
(21/22) 
94% 
(16/17) 
82% 
(144/175) 
Laminitis - 80% 
 (16/20) 
74% 
(20/27) 
52% 
(40/77) 
59% 
(13/22) 
82% 
(14/17) 
63% 
(103/163) 
Hyperhidrosis - 30%  
(6/20) 
26%  
(7/27) 
33% 
(25/77) 
14% 
(3/22) 
59% 
(10/17) 
31% 
(51/163) 
Weight 
Loss/Muscle 
wasting 
42%   
(5/12) 
65%  
(13/20) 
15%  
(4/27) 
47% 
(36/77) 
50% 
(11/22) 
88% 
(15/17) 
48% 
(84/175) 
Abnormal fat 
distribution 
17%  
(2/12)
a 
50% 
(10/20)
a 
33% 
(9/27)
 
29% 
(22/77) 
9%  
(2/22)
a 
12% 
(2/17)
a 
27% 
(47/175) 
Behavioral 
changes 
8%  
(1/12) 
95%  
(19/20) 
19%  
(5/27) 
- 41% 
(9/22) 
82% 
(14/17) 
49% 
(48/98) 
PU/PD 0%  
(0/12) 
55%  
(11/20) 
7%  
(2/27) 
34% 
(26/77) 
32% 
(7/22) 
76% 
(13/17) 
34% 
(59/175) 
Secondary 
infections 
- 35%  
(7/20) 
30%  
(8/27) 
- 36% 
(8/22) 
48% 
(8/17) 
36% 
(31/86) 
a 
= reports describing only suborbital fat distribution. 
 
It is important to note that the prevalence of many of these clinical signs may be 
overestimated due to more advanced cases of PPID selected due to the available 
diagnostic methods. 
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Table 1.2: Signs and symptoms of human Cushing’s syndrome 1 .  
Sign/symptom Frequency (%) 
Truncal obesity 96 
Facial fullness 82 
Diabetes or glucose tolerance 80 
Gonadal dysfunction 74 
Hirsutism, acne 72 
Hypertension 68 
Muscle weakness 64 
Skin atrophy and bruising 62 
Mood disorders 58 
Osteoporosis 38 
Oedema 18 
Polydipsia, polyuria 10 
Fungal infections 6 
 
The group consisted of 302 patients, 239 females and 63 males, with an average age of 
38.4 years (SD : 13.5; range 8-75)
 
 
1 
Adapted from Boscaro et al. (30) 
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Table 1.3: Characteristics of human, canine and equine Cushing’s disease 1. 
 
Clinical Sign Human Canine Equine 
Fatigue + + +/- 
Weight Gain + + - 
Truncal obesity + + - 
Muscle Atrophy + + + 
Osteoporosis + - - 
Hypertension + + - 
Polyuria/polydipsia - + + 
Thinning of skin + + - 
Easy bruising + - - 
Hirsutism + - + 
Alopecia +/- + - 
Hypercortisolism + +  - 
+= present; -= not present  
1 
Adapted from de Bruin et al. (31) 
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Table 1.4: Proxies adapted for basal glucose (mg/dL) and insulin (mU/L) 
concentrations 
1
.  
Proxy Full name Equation 
HOMA-IS Homeostasis model assessment- insulin 
sensitivity 
22.5/ (G X I) 
QUICKI Quantitative insulin sensitivity check index (log[G X I])
-1 
RISQI Reciprocal of the square root of insulin I
-0.5 
MIRG Modified insulin-to-glucose ratio (800 - 0.30 x [I-50]
2
)/(G-
30) 
G= glucose (mg/dL); I= insulin (mU/L) ( 
1
Adapted from Treiber et al. (96) 
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1.6 FIGURES: 
 
Figure 1.1: Schematic drawing showing the four lobes of the pituitary gland. The 
pars intermedia is the region affected when a horse has PPID. 
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Figure 1.2: Schematic drawing illustrating the production of hormones in the 
pituitary gland of the horse. Both the corticotropes of the pars distalis and the 
melanotropes of the pars intermedia produce POMC. In the pars distalis, PC1 converts 
POMC to ACTH and β-lipotropin. In the pars intermedia, PC1 functions similarly, but 
PC2 is also present to further cleave ACTH to α-MSH and CLIP and cleave β-LPH to β-
END. In a horse affected by PPID, PC1 activity increases 4-5 fold and PC2 activity 
increases 2-3 fold. These changes cause ACTH to be produced at a faster rate than it can 
be cleaved and thus there is a net production of ACTH in the pars intermedia. (Adapted 
from Dybdal et al. (39)) 
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Figure 1.3: Schematic drawing of the effects of insulin secretion on the body. Insulin 
secretion increases glucose uptake, glycolysis, glycogen synthesis, protein synthesis and 
ion uptake. When insulin is secreated, gluconeogenesis, glucogenolysis, lipolysis, 
ketogensis and proteolysis decrease. 
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Figure 1.4: Schematic represents the output measures of the minimal model used to 
interpret the FSGTT. Sg represents glucose effectiveness (glucose-mediated glucose 
disposal) and X represents insulin action (insulin-mediated glucose disposal).  AIRg 
represents the acute insulin response to glucose in the first 10 minutes after glucose 
infusion. Insulin sensitivity (Si) is calculated as p3/p2 where p3 is the contribution of 
plasma insulin to the remote compartment and p2 is the fractional rate of insulin clearance 
from the remote compartment (Adapted from (99, 197)) 
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Figure 1.5:  Schematic drawing of the mTOR pathway.  Briefly, insulin stimulates the 
phosphorylation and activation of Akt, which leads to activation of mTOR by inhibiting 
negative regulators of mTOR known as PRAS40 and TSC2. mTOR activates S6Ks and 
inhibits 4E-BPs leading to protein synthesis. 
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Figure 1.6: Schematic drawing of the relationship between protein synthesis and 
breakdown. The mTOR signaling pathway pathways is responsible for some of the 
signaling associated with muscle atrophy. Akt inhibits the transcriptional upregulation of 
Atrogin-1 and MURF1 via inhibition of the FoxO family of transcriptional factors. 
Multiple factors can induce muscle atrophy including TNF-α and IL-1. Briefly, TNF-α 
activates NF-κB, which leads to the activation of MuRF1. A second ligase atrogin-1 is 
upregulated by MAPK p38 (Adapted from Glass (162)). 
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Figure 1.7: Schematic drawing of whole body phenylalanine kinetics.  Entering the 
pool dietary intake (I) is measured phenylalanine in the feed and release of phenylalanine 
from protein degradation (B) is measured by difference of phenylalanine flux and I. 
Leaving the pool phenylalanine oxidation to CO2 (E) is measured by collecting breath 
samples and phenylalanine use in protein synthesis (Z) is measured by subtracting 
phenylalanine oxidation from flux. Conversion to other metabolites (M) is assumed to be 
negligible assuming Tyr intake is equal in all treatment groups. Therefore, phenylalanine 
flux equals the rate phenylalanine enters (I+B) and exits (E+Z+M) the free amino acid 
pool. Flux is calculated from the dilution of the isotope by unlabeled phenylalanine in the 
plasma. 
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Chapter II 
Rationale and Objectives 
2.1 SCOPE OF THESIS 
 
The overall objectives of the presented research are to examine the effects of 
PPID on protein metabolism and insulin sensitivity. The horses used in these studies were 
aged horses older than 20 years of age and consisted of horses with PPID and age-
matched, non-PPID controls. Stable isotope infusion was used to measure whole-body 
protein metabolism and euglycemic hyperinsulinemic clamp (EHC) procedures were 
used to measure insulin sensitivity. Additionally, muscle biopsies were collected in both 
studies to examine the effects of PPID on the mTOR signaling pathway of protein 
synthesis and markers in the protein degradation pathways.  
2.2 RATIONALE 
 
 Estimates of the prevalence of PPID vary greatly, with high estimates suggesting 
15 to 30% of aged horses are affected by PPID (8).  While PPID may affect a large 
number of horses, few studies have been conducted in order to understand the clinical 
signs associated with this multi-faceted condition.  
The effect of PPID on whole body muscle protein synthesis has not been looked 
at in the current literature. Studies of horses with PPID have found that horses with PPID 
have increased proteolysis, atrophied type 2 muscle fibers, sarcoplasmic lipid 
accumulation and increased variation in myofiber size compared to age matched controls 
(16, 17). It is possible that the muscle atrophy associated with these horses may be a 
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result of decreased whole body protein synthesis due to decreased protein synthesis and 
increased protein breakdown. Therefore, it is also important to look at some of these 
factors associated with protein synthesis and breakdown in order to better characterize 
muscle changes associated with PPID. 
Further, the relationship between PPID and insulin sensitivity has not been well 
characterized. Two studies found horses with PPID have decreased insulin sensitivity 
compared to younger cohorts (18, 19); however, the difference in insulin sensitivity 
between horses with PPID and age matched controls has not been studied. Understanding 
the relationship between insulin sensitivity and PPID will be essential to better 
management of horses with PPID. 
Beyond just looking at insulin sensitivity in the horse, it is well known that insulin 
affects a variety of metabolic functions in the body. One example of this is insulin 
stimulating muscle protein synthesis through the mTOR pathway. Since horses with 
PPID are believed to have muscle atrophy, specifically in the form of decreased type 2 
fibers (17); it was important to understand the relationship between insulin response and 
muscle protein synthesis. For this reason, muscle biopsies were taken both before and 
after the euglycemic hyperinsulinemic clamp procedure and analyzed for factors 
associated protein synthesis and degradation in order to better characterize the effects of 
insulin on a muscle level. 
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2.3 SPECIFIC HYPOTHESES AND OBJECTIVES 
2.3.1 Hypothesis 1. 
 Hypothesis 1a: Horses with PPID will have lower rates of whole body protein 
synthesis when compared to aged, non-PPID horses. Hypothesis 1b: Horses with PPID 
will have decreased gluteal muscle mTOR signaling, following feeding, compared to 
aged, non-PPID horses. Hypothesis 1c: Horses with PPID will have an increase in 
protein degradation factors, following feeding, when compared with aged, non-PPID 
horses. 
The objective of the first study entitled, “Pituitary pars intermedia dysfunction 
does not alter whole-body and muscle protein metabolism in aged horses”, was to 
determine the effect of PPID on whole body protein synthesis and the pathways of 
muscle protein synthesis and degradation when compared to aged, non-PPID controls. In 
order to achieve this objective, whole body protein synthesis was assessed using isotope 
infusion techniques (Hypothesis 1a). Additionally, a gluteal muscle biopsy was 
performed 90 minutes post feeding on the day prior to the isotope infusion procedures. 
The muscle samples were prepared and analyzed for factors associated with mTOR 
signaling (Hypothesis 1b) and protein degradation (Hypothesis 1c) using Western 
blotting. 
 
2.3.2 Hypothesis 2. 
 Hypothesis 2a: Horses with PPID will have decreased insulin sensitivity when 
compared to aged, non-PPID horses. Hypothesis 2b: Horses with PPID will have 
decreased mTOR signaling, in response to insulin administration, when compared to 
aged, non-PPID horses. Hypothesis 2c: Horses with PPID will have increased protein 
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degradation factors, in response to insulin administration, when compared to aged, non-
PPID horses. 
 The objective of the second study entitled, “Pituitary pars intermedia dysfunction 
does not affect insulin sensitivity in aged horses”, was to determine if horses with PPID 
had reduced insulin sensitivity compared to age-matched, non-PPID controls. In order to 
achieve this objective, insulin sensitivity was assessed using a euglycemic-
hyperinsulinemic clamp procedure and calculation of two proxies, RISQI and MIRG 
(Hypothesis 2a). Additionally, gluteal muscle biopsies were performed on the day prior 
and immediately after the EHC procedure. The muscle samples were prepared and 
analyzed for factors associated with mTOR signaling (Hypothesis 2b) and protein 
degradation (Hypothesis 2c) using Western blotting. 
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Chapter III 
Pituitary pars intermedia dysfunction does not alter whole-body and muscle protein 
metabolism in old horses. 
3.1 INTRODUCTION 
 
Pituitary pars intermedia dysfunction (PPID; also known as equine Cushing’s 
disease) is believed to affect 15-30% of aged horses (1, 2). The disease results from the 
loss of dopaminergic inhibition of the pituitary pars intermedia leading to increased 
synthesis of proopiomelanocortin-derived peptides, α-melanocyte-stimulating hormone, 
β-endorphin-related peptides, corticotropin-like intermediate lobe peptide and 
adrenocorticotrophin (ACTH) (9). Clinical signs of PPID include hypertrichosis (198), 
laminitis (41) , increased secondary infections (36), decreased insulin sensitivity (19), and 
muscle atrophy (17).  
In human studies, muscle atrophy has been associated with decreased whole-body 
protein synthesis (199). In human patients with Cushing’s disease, whole-body protein 
metabolism was altered due to increased protein breakdown, presumably due to changes 
in body composition and glucocorticoid excess associated with Cushing’s disease (200). 
In horses with PPID, basal cortisol levels are generally within the normal references 
range (14, 15); however, it has been hypothesized that the cortisol circadian rhythm in 
horses with PPID may be abolished leading to increased cumulative cortisol over a 24-
hour period (39). Therefore, it is unclear if similar alterations in whole-body protein 
metabolism will be seen in horses with PPID compared to control horses. Isotope 
infusion techniques to measure whole-body protein metabolism have been used 
extensively in humans studies (187) and they have recently been validated for use in the 
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horse (188). Studies in the horse have looked at the effects of old age on whole-body 
protein synthesis; however, no differences were seen in whole-body protein metabolism 
between the healthy aged (~ 25 yrs) and mature (~11 yrs) horses (201). Even though age 
had no effect on whole-body protein metabolism, it may be possible that differences in 
protein metabolism exist within an aged population, such as horses with PPID, where a 
loss of muscle mass has been previously described (17). 
 Muscle atrophy occurs when the rate of protein degradation exceeds the rate of 
protein synthesis.  PPID is associated with muscle loss due to atrophy of type 2A and 2B 
muscle fibers and loss of type 2B myofibers (17). The overall increase in glucocorticoids 
proposed in horses with PPID (39) may lead to decreased protein synthesis and increased 
protein breakdown at the muscle level. Horses with PPID do have increased expression of 
a factor, m-calpain, which is part of the non-lysosomal calcium protease-dependent 
system associated with protein breakdown (16). The results from the previous study 
suggest that calpains may be associated with muscle atrophy that occurs in horses with 
PPID; however, whether the pathways of protein synthesis or other pathways of protein 
breakdown are involved still requires elucidation.   
Protein synthesis is regulated through the mechanistic (formally mammalian) 
target of rapamycin (mTOR) signaling pathway (106) and previous studies of the horse 
have looked specifically at the factors, protein kinase B (Akt), eukaryotic initiation factor 
4E-binding protein 1 (4E-BP1), and riboprotein S6 (rpS6), which when phosphorylated 
lead to an increase in translation initiation and subsequently protein synthesis (202). Akt 
activation also plays a role in protein degradation as it has been shown to phosphorylate 
and inactivate nuclear transcription factors Forkhead box O (FoxO) (203). When FoxO is 
 58 
 
activated, it increases the expression key genes expressed during proteosomal protein 
degradation, atrogin-1 and muscle RING finger 1 (MuRF1) (203).  Muscle atrophy in the 
horse may also be influenced by decreased protein synthesis due to upregulation of 
negative regulators of protein synthesis, AMP-activated protein kinase (AMPK) (204) 
and myostatin (155). 
The objective of this study was to compare whole-body protein metabolism in 
horses with PPID compared to age-matched, non-PPID controls. Further, the study aimed 
to characterize differences between PPID and age-matched, non-PPID horses in the 
activation of signaling pathways associated with muscle protein synthesis and breakdown 
in response to feeding. 
3.2 MATERIALS AND METHODS 
 
3.2.1 Animals, housing, diets.  
 
All procedures were approved by the University of Kentucky Institutional Animal 
Care and Use Committee (2009- 0562). Twelve horses consisting of six horses with PPID 
and six age-matched, non-PPID controls (CON) were obtained from the Department of 
Veterinary Science’s Maine Chance Farm at University of Kentucky. Horses in the two 
groups were of comparable age (PPID: 25.0±2.5 yrs; mean±SD; CON: 25.7±2.0 yrs) and 
weight (PPID: 542±35 kg; CON: 500±50 kg). Additionally, both groups were comprised 
of 4 mares and 2 geldings and all horses were of moderate body condition score (PPID: 
5.5±0.5 CON: 5.0±0.7; [scale 1-9] (205)). 
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Since the horses used in this study could not be evaluated post-mortem to assess 
the presence of pituitary lesions, two diagnostic methods were used to determine PPID 
status with the greatest possible accuracy (40). Horses were confirmed as PPID based on 
resting ACTH greater than 50 pg/mL and serum cortisol greater than 1 μg/dL 19-20 hours 
after dexamethasone administration. Horses classified as PPID based on these methods 
had many of the clinical signs consistent with PPID, such as hirsutism and hair coat 
abnormalities, hyperhydrosis, muscle atrophy, and a history of laminitis. In April 2012, 
blood samples were collected in EDTA tubes (Vacutainer; Becton-Dickinson, Franklin 
Lakes NJ) and analyzed for ACTH concentration (PPID: 103.6±73.7 pg/mL; CON: 
23.3±8.2 pg/mL) using a hormone assay performed by an external laboratory (Animal 
Health Diagnostic Center; Cornell University, Ithaca, NY). In May 2012, dexamethasone 
suppression tests were performed according to previously described procedures (39) 
where blood samples were collected into glass evacuated tubes containing no additive 
(Vacutainer; Becton-Dickinson, Franklin Lakes NJ) before and 19-20 hours post 
intramuscular administration of dexamethasone (DexaJect; Butler Schein Animal Health, 
Dublin OH ) at 0.04 mg/kg. Serum cortisol was then analyzed using a hormone assay by 
an external laboratory (Animal Health Diagnostic Center; Cornell University, Ithaca, 
NY). 
Horses were adapted to diets and housing for at least 2 weeks prior to the isotope 
infusion procedures. All horses were housed in a single paddock with free access to 
mixed grass hay (mean ± SD, as fed; 10.1± 0.1% crude protein, 33.0± 0.6% acid 
detergent fiber, 50.9± 0.6% neutral detergent fiber, 2.7± 0.4% fat, and 6.5± 0.4% ash), 
water, and salt blocks. Twice daily at 0700 and 1500, horses were fed a commercial 
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concentrate designed for senior horses (mean ± SD, as fed; 14.1± 0.1% crude protein, 
22.5± 0.7% acid detergent fiber, 37.2± 1.3% neutral detergent fiber, 6.2± 0.2% fat, and 
7.4± 0.2% ash) (Purina
® 
Equine Senior
®
 Horse Feed, Purina Mills LLC, Gray Summit, 
MO) individually in stalls  (12g/kg BW/day, split between two meals), with the exception 
of study days where the feeding procedure was modified as described below. Analysis of 
the commercial concentrate and hay were performed by an external laboratory (Dairy 
One Forage Laboratory; Ithaca NY). 
3.2.2 Study procedures. 
 
 On the morning prior to the isotope infusion procedures, horses were weighed 
and blood was collected immediately before (t=0) and 90 minutes after their 0700 meal to 
measure postprandial changes in plasma glucose, insulin and amino acid concentrations. 
According to previous research, horses reach peak amino acid concentration 90 to 180 
minutes following a meal (206).  
The following morning, a catheter (14 gauge × 14.0 cm, Abbocath; Abbott 
Laboratories, North Chicago IL) was inserted into each jugular vein: one for isotope 
infusion and a second for blood collection. In order to determine total CO2 production, 
each horse received a 2 h primed (7.1 μmol/kg BW), constant (6.0 μmol/kg BW/h) 
infusion of a [
13
C]sodium bicarbonate solution using a cordless IV pump attached to a 
surcingle (J-1097 VetPro Infusion Pump, Jorgensen Laboratories Inc., Loveland, CO) 
attachd to a surcingle worn by the horse. The sodium bicarbonate solution was prepared 
by dissolving [
13
C]sodium bicarbonate (Isotec, Miamisburg, OH) in 0.9% sterile saline, 
which was then transferred into a sterile ethylene vinyl acetate bag (Baxter Healthcare, 
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Deerfield IL).  Breath samples were taken at -30, -60, 0, 30, 60, 75, 90, 105 and 120 
minutes of sodium bicarbonate infusion. Breath samples were obtained using a modified 
Equine Aeromask® (Trudell Medical International, London ON, Canada) with a reversed 
one-way valve to allow air to be trapped in gas impermeable bags (Wagner Analysen 
Technik Vertriebs GmbH, Bremen, Germany).  To collect breath samples, horses wore 
the mask for one minute prior to sample collection to allow the air to equilibrate inside 
the mask. Then the bag was attached to the one-way valve and was removed and capped 
once it became full. During sodium bicarbonate infusion, baseline blood samples for 
phenylalanine enrichment were taken at 90 and 120 minutes into the infusion.   
At the end of the two hours, sodium bicarbonate infusion was stopped and a 
second isotope infusion began immediately. Each horse received a 4-hour primed (10.2 
μmol/kgBW), constant (7.2 μmol/kgBW/h) infusion of L-[1-13C] phenylalanine (Isotec, 
Miamisburg, OH) in order to measure whole-body phenylalanine kinetics (207).  The 1.5 
prime to constant ratio was based on the findings of a previous study in horses (188). The 
preparation and administration of the infusion solution and the breath sampling protocols 
were as described above for the [
13
C]sodium bicarbonate infusion. Blood and breath 
samples were taken and feed was given every 30 minutes after the start of isotope 
infusion. 
   On the day of the isotope infusion procedures, horses received 1/48 of their 
daily concentrate allocation every 30 minutes, beginning at least 90 minutes prior to the 
start of the [
13
C]sodium bicarbonate infusion. To minimize changes in plasma 
phenylalanine concentration as a result of the isotope infusion, the meals given prior to 
the start of [1-
13
C]phenylalanine isotope infusion were top dressed with 0.6 mg/kg (3.6 
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μmol/kg BW) of L-phenylalanine powder (L-phenylalanine, Sigma-Aldrich, St. Louis 
MO). 
3.2.3 Muscle biopsy. 
 
Immediately prior to the biopsy, horses were lightly sedated with xylazine 
hydrochloride (0.5 mg/kg; AnaSed; Lloyd, Shenandoah IA) administered IV. The muscle 
biopsy was performed in accordance to previously described procedures (115) where a 
Bergstrom needle was used to aseptically collect muscle (~500 mg) from the gluteus 
medius muscle. Following the biopsy, horses were given 2 g of the non-steroidal anti-
inflammatory phenylbutazone paste (ButaPaste; Butler Animal Health Supply, Dublin 
OH), with additional doses given 24 and 48-hours later. After biopsy, horses were 
returned to their stalls to be monitored. There were no incidences of biopsy site 
infections, with the exception of minor swelling, in any horses in this study. 
3.2.4 Plasma analysis. 
 
The blood samples were transferred into evacuated glass tubes (Vacutainer; 
Becton-Dickinson, Franklin Lakes NJ) coated with sodium heparin and refrigerated (4°C) 
immediately until centrifuged at 1,000 x g at 4°C and plasma was aliquoted and stored at 
-20°C. The two plasma samples taken before and after feeding were analyzed using an 
automated analyzer (YSI 2300 STAT Plus
TM
 Glucose and Lactate Analyzer, YSI Inc., 
Life Sciences, Yellow Springs, OH) to measure plasma glucose concentrations 
enzymatically and a commercially available kit (Coat-A-Count RIA
®
 kit Siemens, 
Healthcare Diagnostics Inc., Deerfield, IL) to measure plasma insulin concentration. The 
kit used has been previously validated for use in horses (208, 209). Additionally, plasma 
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free amino acid concentrations were measured for these samples by HPLC analysis of 
phenyisothiocyanate derivatives, as described previously (115). 
Plasma samples collected during the isotope infusion procedures were analyzed 
by an external laboratory (Metabolic Solutions, Nashua, NH) for the isotopic enrichment 
of a t-butyldimethylsilyl derivative of phenylalanine (m+1) using GC-MS as previously 
described (201, 210).  
3.2.5 Breath sample analysis. 
 
 On the day of isotope infusion, the ratio 
13
CO2:
12
CO2  in exhaled breath samples 
was determined using an isotope selective non-dispersive infrared absorption (NDIR) 
analyzer (IRIS-2; Wagner Analysen Technik Vertriebs, Bremen, Germany). 
3.2.6 Western immunoblot analysis. 
 
 Muscle homogenates were prepared according to previously described 
procedures (116, 202). Briefly, following the muscle biopsy collection, a portion of 
muscle (~100 mg) was homogenized in a lysis buffer. Homogenates were centrifuged at 
10,000 x g for 10 min at 4°C and the supernatant was removed and frozen at -80°C until 
the time of analysis. Protein content of the supernatant was determined using a Bradford 
assay (Bradford Reagent, Sigma-Aldrich, St. Louis MO) and all samples were diluted in a 
Laemmli to a 2 μg/μL concentration to be loaded into polyacrylamide gels. The proteins 
were separated via electrophoresis, transferred to polyvinylidene diflouride membranes 
and incubated for 1 hr in a 5% fat free milk solution with the exception of myostatin, 
which was incubated in a 5% BSA solution. Next, membranes were incubated with the 
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following primary antibodies: Akt (total and phosphorylated Ser
473
; 1:2000 dilutions for 
each; Cell Signaling Technology, Beverly MA), rpS6 (total and phosphorylated Ser
235/236 
and Ser
240/244
; 1:10000 and 1:2000 of each antibody dilutions, respectively; Cell 
Signaling Technology, Beverly MA), 4E-BP1 (total and phosphorylated; 1:1000 dilutions 
of each; Cell Signaling Technology, Beverly MA), AMPKα (total and phosphorylated 
Thr
172
; 1:1000 dilutions of each; Cell Signaling Technology, Beverly MA), FoxO1 (total 
and phosphorylated Ser 
256
; 1:4000 and 1:5000 dilutions, respectively; Santa Cruz 
Biotechnology, Dallas TX), NF-κB p65 (total and phosphorylated Ser536; 1:4000 and 
1:1000 dilutions, respectively; Cell Signaling Technology, Beverly MA), MuRF1 (total; 
1:5000 dilution; ECM Biosciences, Versailles KY), atrogin-1 (total; 1:1000 dilution; 
ECM Biosciences Versailles, KY), myostatin (total;1:10,000 dilution; abcam, Cambridge 
MA) and α-tubulin (total; 1:1000; Cell Signaling Technology, Beverly MA).  Membranes 
were then washed and incubated with a goat anti-rabbit secondary antibody conjugated 
with horseradish peroxidase (BioRad, Hercules CA) for 1 hr at 20°C. Following washing, 
membranes were developed with a chemiluminescent kit (Abersham ECL Plus Western 
Blotting Detection System; GE Healthcare, Piscataway NJ) and developed using a film 
processor (Kodak X-OMAT film processor, Kodak Health Imaging Division, Rochester, 
NY). After developing, membranes were striped and re-probed with a second antibody in 
order to account for the total amount of the protein of interest. In the case of 
phosphorylated proteins, the antibody recognized the total form of the protein. α-tubulin, 
which has previously been used to standardize protein abundance in equine skeletal 
muscle (211), was used to standardize the abundance of MuRF1, atrogin-1 and myostatin, 
because only the total abundance of protein was measured. Band densities were measured 
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using a densitometric computer software (ImageJ, National Institutes of Mental Health, 
Bethesda MD). The abundance of phosphorylated forms of Akt, S6K1, rps6, 4E-BP1, 
AMPK, NF-κB and FoxO1 was corrected for the density of the total protein band and the 
value for the control treatment was set at 1.0 arbitrary units. The abundance of MURF1, 
atrogin-1 and myostatin were determined and compared to abundance of α-tubulin in 
order to correct for total protein. All gels were run in duplicate. 
3.2.7 Calculations. 
 
3.2.7.1 Plasma phenylalanine enrichment   
 
Plasma enrichment of [1-
13
C] phenylalanine, in molecules percent excess, was 
calculated using a previously described formula (212). 
3.2.7.2 Breath CO2 enrichment   
 
For the breath samples collected during the [
13
C] sodium bicarbonate infusion, 
total CO2 production was calculated based on breath CO2 enrichment using a previously 
published formula (213). For all breath samples, the δ enrichment values obtained from 
the nondispersive infrared absorption analyzer was converted to atoms percent excess 
using a previously described formula (213). 
3.2.7.3 Primed, constant infusion, whole-body phenylalanine kinetics   
 
During phenylalanine enrichment, a plateau, defined as at least 4 values having a slope 
not significantly different from 0 (P > 0.05) was determined using linear regression 
analysis (GraphPad Prism 4 Software). The average plasma enrichment at isotopic steady 
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state (plateau) was used to calculate whole-body phenylalanine kinetics. The plateau 
enrichment values were then used to calculate the whole-body phenylalanine flux using 
previously described formulas in the horse (188). Briefly, flux is equal to the amount of 
phenylalanine entering the plasma pool through dietary intake (I), de novo synthesis (N) 
and protein breakdown (B) or leaving the pool through protein synthesis (Z), oxidation 
(E) or conversion to other metabolites (M): 
Q= I + N + B = Z + E + M. 
Intake was determined by multiplying dietary phenylalanine intake by 0.5 to account for 
prececal phenylalanine digestibility (214) and the dietary phenylalanine that is extracted 
during first-pass splanchnic metabolism in other monogastric species (215, 216) . In the 
horse, phenylalanine is an indispensible amino acid, so de novo synthesis does not occur; 
therefore protein breakdown can be estimated by: 
B= Q – I. 
Phenylalanine oxidation was calculated using the equations previously described (191). 
Non-oxidative phenylalanine metabolism can be calculated by taking the difference 
between phenylalanine flux and oxidation and is used as an indication of whole-body 
protein synthesis. The major non-CO2 product of phenylalanine metabolism is tyrosine; 
however, in the current study, the only source of dietary tyrosine was the pelleted 
complete feed, which all of the horses received at the same intake level corrected for 
body weight. Therefore, any reduction in whole-body phenylalanine oxidation would 
suggest an increase in phenylalanine use for whole-body protein synthesis. 
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3.2.8 Statistical analysis.  
 
All data were analyzed using the mixed procedure of SAS (version 9.3; SAS Institute; 
Cary NC) and data were considered significant at P < 0.05. Statistical trends were 
considered at 0.05 < P <0.10.  
Analyses of pre-feeding and post-feeding plasma metabolite concentrations were 
assessed using a repeated-measures analysis, with group, time, and the interaction 
between group and time as the fixed effects and horse nested in group as the random 
effects. The variance-covariance matrix was chosen for each repeated-measures analysis 
based on the lowest value for Schwarz’s Bayesian Criterion. Phenylalanine kinetics 
parameters and western immunoblot data were analyzed using a 1-way ANOVA with 
PPID status (group) as the fixed effect and horse nested in group as the random effect.  
All data are presented as least square means and pooled standard errors. 
3.3 RESULTS 
 
3.3.1 Plasma insulin, glucose, and amino acids.  
 
Plasma insulin, glucose, and amino acid concentrations were measured prior to 
feeding and 90 minutes post-feeding. Plasma insulin (Table 3.1) and glucose (Table 3.1) 
concentrations increased post-feeding (P< 0.01). Plasma glucose concentration was 
higher post-feeding in the PPID horses compared to the CON horses (P= 0.02); however, 
plasma insulin concentrations were not different between PPID and CON horses. There 
was no effect of the interaction between time and PPID status on either plasma glucose or 
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insulin concentrations (P> 0.05). Plasma amino acid concentrations were not affected by 
time, PPID status or the interaction between time and PPID status (P > 0.05) (Table 3.1).  
3.3.2 Western immunoblot data. 
 
There was no effect of PPID status on the post-feeding activation of Akt at Ser
473 
(P= 0.93; Figure 3.1), rpS6 at Ser
235/236 & 240/244 
(P=  0.20; Figure 3.1), 4E-BP1 at Thr 
37/46 
(P= 0.36 ; Figure 3.1), NFκB p65 at Ser536  (P= 0.48; Figure 3.2), AMPKα at Thr172 (P= 
0.54; Figure 3.3), myostatin (P= 0.27; Figure 3.3), FoxO1 (P= 0.85; Figure 3.4), MuRF1 
(P= 0.67; Figure 3.4) or atrogin-1 (P= 0.53; Figure 3.4) (P > 0.05). 
3.3.3 Whole-body phenylalanine kinetics.  
 
There was no effect (P > 0.05) of PPID status on carbon dioxide production, 
phenylalanine flux, phenylalanine intake, phenylalanine oxidation, phenylalanine release 
from protein breakdown and non-oxidative phenylalanine disposal (Table 3.2).  
3.4 DISCUSSION 
 
Although a previous study examined some of the pathways associated with 
muscle protein breakdown in horses with PPID compared to age-matched controls (16), 
to the best of the authors’ knowledge, this was the first study to compare whole-body 
protein synthesis and mTOR signaling between horses with PPID and age-matched, non-
PPID horses. The current study showed that despite an increase in plasma insulin and 
glucose concentrations post-feeding, there was no concurrent increase in the plasma 
concentration of any of the indispensable amino acids 90 minutes following a meal. 
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There were no differences in whole-body protein kinetics between the PPID and CON 
horses, nor were differences seen in the abundance of any of the signaling factors 
associated with protein synthesis and degradation that were studied. These findings 
suggest that although PPID status does not affect whole-body protein metabolism or any 
of the signaling pathways studied, advanced age may lead to a decreased ability to release 
amino acids into the bloodstream post-feeding. 
The only significant difference that was measured between the PPID and CON 
groups in this study was that the PPID horses had a higher plasma glucose concentration 
in response to feeding when compared to the CON horses, although pre-feeding values 
were not different between the groups. Despite the differences in glucose concentration, 
there were no differences in basal insulin concentrations or insulin concentrations post-
feeding between the two groups of aged horses.  This suggests that the PPID horses may 
some dysregulation in insulin-mediated glucose uptake, since similar concentrations of 
insulin were not able to stimulate glucose uptake as effectively in the PPID horses. 
Previous studies have suggested increased insulin resistance in horses with PPID (18, 19) 
and increased incidence of hyperinsulinemia (1); however, in all of these previous studies 
the control group was much younger than the PPID horses due to the nature of PPID 
affecting primarily aged horses. Differences in insulin sensitivity may help to explain 
some of the associations between muscle atrophy and PPID. Understanding differences in 
insulin sensitivity in horses with PPID compared to age-matched, non-PPID controls is 
an area where additional research is warranted. 
 In the current study, plasma glucose and insulin concentrations at 90 minutes 
post-feeding were increased compared to pre-feeding levels; however, feeding did not 
 70 
 
result in an increase in the plasma concentrations of any of the indispensable amino acids. 
Previous research in horses has shown that plasma amino acid concentrations reach peak 
concentrations around 90 minutes post-feeding (206); therefore the lack of postprandial 
increase in the plasma amino acids at the t= 90 min sample in the current study was 
unexpected. We have previously shown that feeding of a high protein meal (1.32g 
protein/kg BW, divided between 2 meals which were separated by 30 minutes) resulted in 
large increases in plasma glucose, insulin and amino acids concentrations and also 
resulted in an increase in the activation of mTOR signaling factors in the skeletal muscle 
of both mature (115, 116) and growing horses (116).  The current study provided 0.86 
g/kg BW protein in the meal, which is lower than the previous studies of mTOR signaling 
in horses (115, 116); however, it is greater than in another previous study (0.55 g 
protein/kg BW) (188) in mature horses where increases in plasma amino acid 
concentrations were measured at 120 min post-feeding. Therefore, based on the literature, 
it appears unlikely that the timing of the postprandial sample was not appropriate or that 
the amount of protein fed was inadequate to measure the expected postprandial increase 
in plasma amino acids concentrations. 
It is possible that the lack of a postprandial increase in plasma amino acid 
concentrations is a function of advanced age of the horses studied (~25 years) and 
therefore affected both groups of horses in the current study. This hypothesis is consistent 
of studies in old rats, which revealed that age alters splanchnic extraction of amino acids. 
In aged rats, arterial plasma concentrations of AA were lower (20-30% less on average) 
when compared to adult rats infused with amino acids (217). In horses, there is some 
evidence to support that protein digestion may decrease with advanced age. In an early 
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study, apparent crude protein digestion was reduced in aged horses (~25 yrs) when 
compared with younger horses (~2 yrs) (195); however, in later studies of aged horses, 
protein digestion was within the normal range of apparent protein digestion reported for 
younger horses (196). Therefore, it is difficult to speculate whether the lack of 
postprandial increase in plasma amino acid concentrations in the current study was due to 
age-related alterations in dietary protein digestibility. The lack of increase in plasma 
amino acid concentrations in these old horses is of interest because it could affect the 
amount of anabolic stimuli that is present to stimulate the postprandial increase in muscle 
protein accretion. The underlying cause of the lack of postprandial increase in plasma 
amino acid concentrations in the aged horses in the current study warrants additional 
research. 
The muscle atrophy that has been described in horses with PPID may be due to 
increased circulating inflammatory cytokines, because these have been shown to 
stimulate protein breakdown (178). In the horse, inflammation has been shown to 
increase with advancing age as part of a process known as inflamm-aging (218). 
Interestingly, horses with PPID have been shown to have decreased (219) or similar (16) 
expression of several inflammatory cytokines when compared to healthy aged-matched 
controls. In the present study, inflammation was not measured directly, but no differences 
were found in the relative abundance of phosphorylated NF-κB between the PPID and 
CON. The phosphorylation and activation of NF-κB is stimulated by inflammatory 
cytokines (179), thus it is unlikely that there was a difference in inflammatory signaling 
in the skeletal muscle between the two groups of aged horses in the current study. 
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In studies of aging in humans, some studies have found that the rates of whole 
body muscle protein synthesis declined with age (187) , whereas other studies have found 
that aging does not alter whole-body muscle protein synthesis (192). The authors 
hypothesized that the lack of difference in protein anabolic responses may have been due 
to similar muscle mass index and level of physical activity between the elderly and young 
group (192). It has been demonstrated that up to 87% of the variance seen in whole-body 
protein kinetics is due to differences in fat free mass (187). In the current study, fat free 
mass was not measured directly, but both groups were of moderate body condition score 
suggesting differences in fat-free mass between the two groups was minimal. This is 
consistent with another study where no differences in whole-body protein metabolism 
were measured between aged and mature horses of similar body condition scores (201). 
In the current study, no significant differences were seen in any of the measures of 
whole-body protein kinetics between the PPID and CON groups. These results differ 
from what would be expected based on previous studies that have shown increased 
muscle atrophy and increased expression of a factor associated with protein breakdown 
pathway non-lysosomal calcium protease-dependent systems. The results from the 
current study also differ from human studies where protein breakdown was increased in 
patients with Cushing’s disease (200), further highlighting the differences between 
human Cushing’s disease and PPID.   
It is possible that no differences in whole-body protein kinetics were seen due to 
the horses that were included in this study. All of the aged horses, regardless of PPID 
status, included in the present study were relatively healthy, capable of being managed in 
a group setting and did not exhibit visible signs of the extreme losses in fat free mass that 
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can occur with age. It is possible that if more advanced cases of PPID had been included 
in the current study, differences in whole-body protein metabolism may have been 
measured between the PPID and CON groups. Whole-body protein kinetics only give 
information about overall rates of protein synthesis and breakdown occurring in the body, 
but do not provide specific information about the contribution of the individual tissues. 
Therefore, although no differences in whole-body protein synthesis or breakdown were 
seen in the present study, it is still possible that changes may exist on the muscle level 
and thus the activation of the signaling pathways were studied in the skeletal muscle. 
 Protein synthesis is regulated through the mTOR pathway. Briefly, Akt is 
activated by insulin and subsequently activates downstream factors of mTOR signaling, 
rps6 and 4E-BP1, leading to protein synthesis. Glucocorticoids, which have been 
hypothesized to be elevated over a 24-hr period in horses with PPID, have been shown to 
decrease Akt phosphorylation in the horse (211). In the current study, no differences were 
seen between the PPID and CON groups in the phosphorylation of any of the mTOR 
signaling factors studied, suggesting that PPID status does not alter muscle protein 
synthesis in response to feeding in the horse. Protein synthesis is stimulated by insulin 
and negatively affected by glucocorticoid excess and this suggests that insulin sensitivity 
and cumulative daily glucocorticoids may not be different between the two groups in the 
current study, although this was not measured. 
 Myostatin acts as a negative regulator of skeletal muscle mass by inhibiting 
activation of factors associated with mTOR signaling (155). Dexamethasone 
administration, which has been shown to decrease skeletal muscle mass (152), leads to 
increased myostatin expression in rats (153).  In the current study, no differences were 
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seen in muscle abundance of myostatin, which is consistent with previous studies of 
PPID horses compared to age-matched controls (16). Another negative regulator of 
protein synthesis is AMPK, a sensor of cellular energy, that is activated by rising AMP 
levels as a result of energy starvation and results in mTOR inhibition (220). Due to the 
differences in plasma glucose post feeding in the current study, it would be possible that 
differences in AMPK phosphorylation could exist between the two groups of horses. 
However, no differences were seen in phosphorylation of AMPK between the PPID and 
CON groups, indicating no differences in cellular energy status exist between the two 
groups of aged horses. 
In addition to activating protein synthesis, Akt phosphorylation also has the 
ability to affect protein breakdown through phosphorylation and subsequent inactivation 
of FoxO (203), leading to an increase in protein breakdown through the ubiquitin-
proteosomal pathway. FoxO phosphorylation has been show to increase the expression of 
MuRF1 and atrogin-1, two genes highly associated with muscle atrophy (166). Due to the 
muscle atrophy previously associated with PPID (16),  it would be expected to see an 
increase in factors associated with ubiquitin-proteosomal protein breakdown pathway in 
the PPID versus CON horses; however, this was not observed in the present study. There 
were no differences seen between PPID and CON groups in the phosphorylation of 
FoxO1, which is consistent with the lack of differences in the expression of MuRF1 and 
atrogin-1. In a previous study of protein breakdown in horses with PPID versus age 
matched controls, no significant differences were detected the expression of the major 
proteolytic systems between the two groups with the exception of m-calpain, which had 
greater expression in horses with PPID (16). Therefore, the results from the current study 
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generally support the results from the previous study (16) that it is not the ubiquitin-
proteosomal pathway of protein breakdown that is affected by PPID status in aged horses. 
 Alternatively, it is possible that the muscle biopsy at 90 minutes post-feeding did 
not effectively capture differences in the protein synthesis and breakdown pathways 
between the two groups of aged horses. Further, the study only looked at the abundance 
or phosphorylation of these factors post-feeding, so it is possible that response to other 
anabolic stimuli, such as exercise, may in fact be different between the two groups. In the 
current study, muscle biopsies were taken at 90 minutes post-feeding based on previous 
studies of younger horses (115, 116). However, in the current study, no changes were 
seen in plasma amino acid concentrations post-feeding, indicating 90 minutes may not 
have been an appropriate time to take the muscle biopsy in aged horses. Since it is known 
amino acids stimulated mTOR signaling (221), differences in the signaling pathways 
between the two groups may have been missed. Further, the current study did not take a 
pre-feeding muscle biopsy, so it is impossible to speculate if the meal was able to 
stimulate a post-prandial increase in mTOR signaling, as seen in previous studies (115, 
116). In human studies, aging has been shown to decrease the responsiveness of mTOR 
signaling in response to anabolic stimuli, but differences are not always seen in a basal 
state (222). The inability to stimulate mTOR or suppress protein breakdown in response 
to feeding could be a potential mechanism to explain muscle loss as seen in aged horses 
and in particular horses with PPID (17), although additional research would be needed to 
specifically examine this hypothesis. 
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3.5 CONCLUSION 
 
 The study highlights the importance of understanding amino acid requirements 
and digestibility in all aged horses, because none of the horses in this study showed an 
increase in plasma amino acid concentration in response to feeding. Although muscle 
atrophy has been shown to be associated with PPID, no differences were seen in whole-
body protein kinetics between the two groups of aged horses in the current study. 
Additionally, although there is some evidence that insulin sensitivity may be lower in 
horses with PPID, it does not seem to affect abundance or phosphorylation of the factors 
associated with protein synthesis and breakdown that were studied in the muscle. None of 
the factors associated with protein synthesis and breakdown in the muscle were different 
between the two groups; supporting the idea that whole-body protein metabolism is not 
affected by PPID status. The mechanisms underlying the loss of muscle mass in horses 
with PPID requires additional investigation. 
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3.6 TABLES 
 
Table 3.1. Glucose, insulin and amino acid concentrations in PPID and CON horses 
before (0 min) and 90 min following a meal
1 
 CON  PPID  p-values 
 0 min 90 min 0 min 90 min Pooled SE Group Time Group *Time 
Glucose
2 
4.73 5.31
a 
 5.35 6.28
b
* 0.27 0.02 0.01 NS 
Insulin
3 
9.7 46.5*  20.2 61.4* 8.7 NS 0.001 NS 
Histidine
4 
79 78  75 84 10 NS NS NS 
Isoleucine 70 80  69 71 4 NS NS NS 
Leucine 126 131  131 128 9 NS NS NS 
Lysine 105 125  109 119 12 NS NS NS 
Methionine 44 47  43 41 3 NS NS NS 
Phenylalanine 68 73  59 61 6 NS NS NS 
Threonine 124 129  149 152 12 NS NS NS 
Tryptophan 13 13  12 13 1 NS NS NS 
Valine 245 261  272 267 14 NS NS NS 
1
Values are lease square means *Values that differed significantly (P < 0.05) from 
baseline. 
a,b
 Values that were significantly different between the CON and PPID group at 
the same time point. 
2
Plasma glucose concentrations are reported as least squares means in mmol/L 
3
Plasma insulin concentrations are reported as least squares means in µIU/mL. 
4
Plasma amino acid concentrations are reported as least squares means in µmol/L. 
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Table 3.2: Whole-body phenylalanine kinetics in PPID and CON horses
1
  
 CON PPID Pooled SE P 
Phenylalanine flux, μmol·kg-1·h-1 38 39 1 NS3 
Carbon dioxide production, μmol·kg-1·h-1 
Phenylalanine entering the free phenylalanine pool 
14 15  1 NS 
Phenylalanine from dietary intake
3
, μmol·kg-1·h-1 7 7  0 NS 
Phenylalanine from protein breakdown
2
  
μmol·kg-1·h-1 
 
Phenylalanine leaving the free phenylalanine pool 
 
30  31 1 NS 
Phenylalanine oxidation
3
, μmol·kg-1·h-1 9 8 1 NS 
Non-oxidative phenylalanine disposal, 
μmol·kg-1·h-1 
29 31 1 NS 
1
 Values are least square means.  Labeled means in a row without a common letter differ, 
P < 0.05.  
*
Differs from the rate of non-oxidative phenylalanine disposal for that 
treatment, P < 0.05. 
2
The following stochastic model of phenylalanine kinetics was used: flux = rate of 
phenylalanine entry = rate of phenylalanine leaving; rate of phenylalanine entry = 
phenylalanine intake + phenylalanine release from protein breakdown; rate of 
phenylalanine leaving = phenylalanine oxidation + non-oxidative phenylalanine disposal 
3
NS, not significant, P > 0.05. 
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3.7 FIGURES 
 
Figure 3.1. Postprandial gluteal muscle phosphorylation of factors involved in the 
upregulation of protein synthesis, Akt at Ser
473
, rpS6 at Ser
235/236 & 240/244
, and 4E-
BP1 at Thr 
37/46 
in CON (white bars) and PPID (black bars) horses. The 
phosphorylated forms of the translation initiation factors were corrected by the respective 
total form abundance, with the value for CON horses set to 1.0 AU. Values are least 
square means ± pooled SE, n=6 per group. Representative images of the immunoblots are 
shown above.  
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Figure 3.2. Postprandial gluteal muscle phosphorylation of NFκB p65 at Ser536, an 
indicator of inflammatory status, in CON (white bars) and PPID (black bars) 
horses. The phosphorylated form of NFκB was corrected by the respective total form 
abundance, with the value for CON horses set to 1.0 AU. Values are least square means ± 
pooled SE, n=6 per group. Representative images of the immunoblots are shown above. 
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Figure 3.3. Postprandial gluteal muscle phosphorylation of AMPKα at Thr172 and 
relative abundance of myostatin, negative regulators of protein synthesis, in CON  
(white bars) and PPID (black bars) horses. The phosphorylated form of αAMPK was 
corrected by the respective total form abundance, and myostatin abundances were 
normalized to α-tubulin, with the value for CON horses set to 1.0 AU. Values are least 
square means ± pooled SE, n=6 per group. Representative images of the immunoblots are 
shown above. 
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Figure 3.4. Postprandial gluteal muscle phosphorylation of FoxO1 and relative 
abundances of atrogin-1 and MuRF1
 
in CON (white bars) and PPID (black bars) 
horses. The phosphorylated form of FoxO1 was corrected by the respective total form 
abundance and atrogin-1 and MuRF1 abundances were normalized to total α-tubulin, 
with the value for CON horses set to 1.0 AU. Values are least square means ± pooled SE, 
n=6 per group. Representative images of the immunoblots are shown above. 
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Chapter IV 
Pituitary pars intermedia dysfunction does not affect insulin sensitivity in aged horses. 
4.1 INTRODUCTION 
 
Pituitary pars intermedia dysfunction (PPID), also known as equine Cushing’s 
disease, is believed to affect 15-30% of aged horses (1, 2). The disease is caused by a 
hypertrophy, hyperplasia, or adenoma formation on the pars intermedia of the pituitary 
gland and typically occurs in horses older than 15 years of age (5). Clinical signs of PPID 
include hypertrichosis (198), muscle atrophy (17), laminitis (41) , increased secondary 
infections (36) and decreased insulin sensitivity (19).  
Insulin resistance is defined as a condition in which normal concentrations of 
insulin produce a subnormal physiologic response (66).  Currently, two studies have 
investigated the effects of PPID on insulin sensitivity in the horse; however, in both 
studies it is likely that the PPID horses were much older than the control horses, due to 
the nature of PPID affecting primarily aged horses (5). Garcia and Beech (18) determined 
that horses with PPID (> 12 yrs old) did not respond to intravenous glucose 
administration with an increase in insulin similarly to control horses (3 to 13 years old) 
on the same diet. Another study used a euglycemic hyperinsulinemic clamp (EHC) and 
found that horses with PPID (~21 yrs) had decreased insulin sensitivity compared with 
healthy controls (~10 yrs) (19) . Insulin sensitivity has been shown to decrease with age 
(88); therefore, it is likely age was a confounding factor in both of these studies and it is 
still unknown whether insulin sensitivity is different between PPID and non-PPID aged 
horses.  
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Additionally, PPID has been associated with muscle atrophy (17). Muscle atrophy 
occurs when the rate of protein degradation exceeds the rate of protein synthesis.  The 
signaling pathways associated with both protein accretion and breakdown are affected by 
insulin (171, 223); therefore, insulin resistance could be a potential mechanism to explain 
the muscle atrophy that occurs in the horse. It has been demonstrated that insulin 
increases the phosphorylation of factors in the mechanistic target of rapamycin (mTOR) 
signaling pathway, which is responsible for muscle protein synthesis (106), specifically 
factors protein kinase B (Akt), eukaryotic initiation factor 4E-binding protein 1 (4E-
BP1), and riboprotein S6 (rpS6) are phosphorylated, ultimately leading to an increase in 
protein synthesis. A previous study determined that there was an increase in the 
activation of mTOR signaling factors of the skeletal muscle of mature (~14 year old) 
horses in response to hyperinsulinemia (Urschel et al., unpublished); however, there has 
only been limited research regarding muscle protein degradation in the horse (16). 
Increased circulating inflammatory cytokines have been shown to induce loss of skeletal 
muscle proteins through the activation of NFκB (179); however, inflammatory cytokines 
in horses with PPID have been shown to have similar (16)  or decreased (219) expression 
when compared to age-matched controls. Akt activation also plays a role in protein 
degradation as it has been shown to phosphorylate and inactivate nuclear transcription 
factors Forkhead box O (FoxO) (203). When FoxO is activated, it increases the 
expression of E3 ubiquitin ligases, atrogin-1 and muscle RING finger 1 (MuRF1), key 
genes expressed during protein degradation (203).  Muscle atrophy in the horse may also 
be influenced by decreased protein synthesis due to AMP-activated protein kinase 
(AMPK) (204) and myostatin (155) , both negative regulators of protein synthesis.   
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The objective of this study was to compare insulin sensitivity in horses with PPID 
compared to age-matched, non-PPID controls using a dynamic test and proxies to 
measure insulin sensitivity. Further, the study aimed to characterize differences in the 
activation of signaling pathways associated with muscle protein synthesis and breakdown 
in response to insulin administration between the PPID and age-matched, non-PPID 
control horses. 
4.2 MATERIALS AND METHODS 
 
The University of Kentucky Institutional Animal Care and Use Committee approved all 
procedures in this study (2009-0562).  Horses were obtained from an already established 
herd of aged horses housed at the Department of Veterinary Science’s Maine Chance 
Farm at the University of Kentucky.  
4.2.1 Animals, housing and diets. 
 
Twelve horses, older than 20 years of age, were classified as either PPID (n=6; 25.0±2.5 
yrs; mean±SD) or age-matched, non-PPID control (CON) (n=6; 25.7±2.0 yrs). The 
selected horses consisted of 10 Thoroughbreds (PPID: n=5; CON: n=5), one mixed breed 
horse (CON: n=1) and one Quarter horse (PPID: n=1). Both the PPID and CON group 
were comprised of 4 mares and 2 geldings of moderate body condition scores (PPID: 
5.5±0.5; CON: 5.0±0.7; [scale 1-9] (205)). Horses classified as PPID exhibited a variety 
of the classic physical signs associated with the disease including hirsutism, 
hyperhydrosis, muscle atrophy, a history of laminitis, and hair coat abnormalities (8). 
PPID classification was confirmed based on a resting ACTH greater than 50 pg/mL and 
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serum cortisol greater than 1 μg/dL 19-20 hours following dexamethasone administration. 
Blood for the plasma ACTH hormone assay was collected in April using EDTA tubes 
(Vacutainer; Becton-Dickinson, Franklin Lakes, NJ) and sent to an external laboratory 
for analysis (Animal Health Diagnostic Center; Cornell University, Ithaca, NY) that used 
a chemiluminescent immunoassay to measure plasma ACTH. Plasma ACTH 
concentrations were well above the 50 pg/mL cutoff for PPID horses (98.4±73.7 pg/mL) 
and much lower in the CON horses (23.3±8.2 pg/mL). Dexamethasone suppression tests 
were performed in May according the previously described procedures (39). Blood 
samples were collected into glass evacuated tubes containing no additive (Vacutainer; 
Becton-Dickinson, Franklin Lakes, NJ) before and 19-20 hours following an 
intramuscular injection of dexamethasone at a dose of 0.04 mg/kg (DexaJect; Butler 
Schein Animal Health, Dublin OH). Serum cortisol concentrations were determined by 
an external laboratory (Animal Health Diagnostic Center; Cornell University, Ithaca, 
NY), which used a chemiluminescent immunoassay to measure cortisol concentrations. 
Cortisol was suppressed in the CON horses (0.46±0.32 µg/dL), but it did not suppress in 
the PPID horses (2.27±0.92 µg/dL) consistent with a diagnosis of PPID. Horses were 
returned to the Department of Veterinary Science’s herd of horses at the end of the study 
and therefore it was not possible to perform a post-mortem examination for a more 
definitive diagnosis of pituitary pars intermedia abnormalities. 
All horses were housed in one paddock with free access to mixed grass hay (mean 
± SD, as fed; 10.1± 0.1% crude protein, 33.0± 0.6% acid detergent fiber, 50.9± 0.6% 
neutral detergent fiber, 2.7± 0.4% fat, and 6.5± 0.4% ash), water, and salt blocks. Horses 
were fed a commercial concentrate (mean ± SD, as fed; 14.1± 0.1% crude protein, 22.5± 
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0.7% acid detergent fiber, 37.2± 1.3% neutral detergent fiber, 6.2± 0.2% fat, and 7.4± 
0.2% ash) (Purina
® 
Equine Senior
®
 Horse Feed, Purina Mills LLC, Gray Summit, MO) 
individually in stalls twice daily (12g/kg BW/day), divided equally between meals at 
0700 and 1500. Feed and hay samples were collected throughout the study by random 
sampling and analyzed by Dairy One Forage Laboratory (Ithaca, NY). Horses were 
adapted to the diets and housing for a minimum of 2 weeks prior to the euglycemic 
hyperinsulinemic clamp (EHC) procedures 
4.2.2 Experimental design and procedures.  
 
4.2.2.1 Determination of basal values.  
 
Prior to the day of the EHC procedures, horses were kept in stalls with free access to hay 
and water. Twenty-four hours prior to the end of the EHC procedure, a 10 mL blood 
sample was collected, via jugular vein venipuncture, to measure basal values for the 
plasma concentrations of glucose, insulin and amino acids. Immediately after the blood 
sample, horses were lightly sedated with xylazine hydrochloride (0.5 mg/kg BW) 
administered IV (AnaSed; Lloyd, Shenandoah, IA). Then, a muscle biopsy was 
performed in accordance with previously described procedures (202) where a muscle 
tissue sample (~500 mg) was collected from the gluteus medial muscle using a Bergstrom 
needle. Following the biopsy, horses were given 2 g of a non-steroidal anti-inflammatory 
phenylbutazone (ButaPaste; Butler Animal Health Supply, Dublin, OH) and a meal was 
fed. Horses were kept in stalls overnight (~18 hours) with free access to hay and water.  
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4.2.2.2 The EHC procedure 
 
The following day, catheters (14 gauge X 14.0 cm, Abbocath; Abbott 
Laboratories, North Chicago, IL) were inserted into each jugular vein after the overlying 
skin had been desensitized with 2% lidocaine (Lidocaine Injectable; Sparhawk 
Laboratories, Inc., Lenexa, KS). One catheter was used for infusion of a 50% dextrose 
solution (Bimeda Inc., Le Sueur MN) and insulin (Humulin N; Eli Lilly and Company, 
Indianapolis, IN) while the second catheter was used for obtaining blood samples.  
Immediately (-25 to -5 min) prior to the EHC procedures, four blood samples 
were taken at 5-minute increments and analyzed for glucose concentration using a hand 
held glucometer (Accu-Chek Aviva Plus; Roche Diagnostics, Indianapolis, IN).  These 
values were then averaged in order to determine resting glucose concentration. Horses 
were outfitted with a surcingle and two infusion pumps. The insulin solution was 
prepared by diluting recombinant human insulin into a 0.9% sterile saline solution for a 
final concentration of 360 mU/mL. A priming dose of 0.4mU/kg BW insulin was given at 
t=0 and then insulin infusion began at a rate of 1.2 mU/kg BW/minute as recommended 
by previous research (224, 225), using a cordless intravenous pump (J-1097 VetPro 
Infusion Pump, Jorgensen Laboratories Inc., Loveland, CO).  Insulin infusion at this rate 
has also been shown to activate factors in the mTOR pathway in the gluteus medius 
muscle of mature horses (Urschel et al., unpublished). The EHC procedure was 
performed as previously described (104), where insulin was infused at a constant rate and 
the glucose rate was adjusted to maintain euglycemia. Once the procedure began, small 
blood samples were taken every 5 minutes and glucose concentrations were measured 
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with the hand held glucometer.  When the blood glucose concentration fell below 10% of 
the average baseline values, the infusion of the 50% dextrose solution was initiated using 
a second peristaltic pump. Dextrose infusion was then adjusted throughout the procedure 
in order to keep glucose values within 10% of baseline. In addition to the small blood 
samples, 10 mL blood samples were taken every 15 minutes over the 120-minute 
procedure for the determination of plasma glucose, insulin and amino acid concentration. 
The blood samples were transferred into evacuated glass tubes (Vacutainer; Becton-
Dickinson, Franklin Lakes NJ) coated with sodium heprin and refrigerated (4°C) 
immediately until centrifuged at 1,500 x g at 4°C. Plasma was aliquoted and stored at -
20°C until the time of analysis. 
Following the EHC procedure, a second muscle biopsy was taken from the 
opposing gluteus medius muscle using the same techniques as basal muscle biopsy. For 
this biopsy, insulin and glucose infusion continued until the biopsy sample was collected 
and thus this biopsy will be referred to as the insulin stimulated state biopsy (INS). 
Similarly to the basal biopsy, horses were given 2 g of the non-steroidal anti-
inflammatory phenylbutazone (ButaPaste; Butler Animal Health Supply, Dublin, OH) 
immediately following the muscle biopsy and then 24 and 48-hours following the 
procedure. After the INS biopsy, insulin and dextrose infusion was stopped and horses 
were returned to their stalls to be monitored. There were no evidence of any incidences of 
hypoglycemia following the second biopsy or any signs of biopsy site infections, with the 
exception of minor swelling, in any horses in this study. 
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4.2.3 Plasma analysis.  
 
An automated analyzer (YSI 2300 STAT Plus
TM 
Glucose and Lactate Analyzer, 
YSI Inc., Life Sciences, Yellow Springs, OH) was used to measure plasma glucose 
concentrations enzymatically. A commercially available kit (Coat-A-Count RIA
®
 kit 
Siemens, Healthcare Diagnostics Inc., Deerfield, IL) was used to analyze plasma insulin 
concentrations. The kit used has been previously validated for use in horses (208, 209). 
Plasma free amino acid concentrations were measured by use of HPLC analysis of 
phenylisothiocyanate derivatives, as described elsewhere (202). 
4.2.4 Western immunoblot analysis. 
 
 Muscle homogenates were prepared as previously described (202). Briefly, 
following the muscle biopsy collection, a portion of muscle (~100 mg) was homogenized 
in a lysis buffer and centrifuged at 10,000 x g for 10 min at 4°C. Then the supernatant 
was removed and frozen at -80ºC until the time of analysis. Supernatant protein content 
was determined using a Bradford assay (Bradford Reagent, Sigma-Aldrich, St. Louis 
MO). All samples were diluted in a Laemmli to a 2 μg/μL concentration prior to being 
loaded into polyacrylamide gels. The proteins were separated via electrophoresis and then 
transferred to polyvinylidene diflouride membranes, as previously described (148). All 
proteins were incubated for 1 hr in a 5% fat free milk solution with the exception of 
myostatin which was incubated in a 5% BSA solution. Then, membranes were incubated 
with the following primary antibodies: Akt (total and phosphorylated Ser
473
; 1:2000 
dilutions for each; Cell Signaling Technology, Beverly MA), rpS6 (total and 
phosphorylated Ser
235/236 
and Ser
240/244
; 1:10000 and 1:2000 of each antibody dilutions, 
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respectively; Cell Signaling Technology, Beverly MA), 4E-BP1 (total and 
phosphorylated; 1:1000 dilutions of each; Cell Signaling Technology, Beverly MA), 
AMPKα (total and phosphorylated Thr172; 1:1000 dilutions of each; Cell Signaling 
Technology, Beverly MA), FoxO1(FKHR) (total and phosphorylated Ser 
256
; 1:4000 and 
1:5000 dilutions, respectively; Santa Cruz Biotechnology, Dallas TX), NF-κB p65 (total 
and phosphorylated Ser
536
; 1:4000 and 1:1000 dilutions, respectively; Cell Signaling 
Technology, Beverly MA), MuRF1 (total; 1:5000 dilution; ECM Biosciences, Versailles 
KY), atrogin-1 (total; 1:1000 dilution; ECM Biosciences Versailles, KY), myostatin 
(total;1:10,000 dilution; abcam, Cambridge MA) and α-tubulin (total; 1:1000; Cell 
Signaling Technology, Beverly MA). Membranes were then washed and incubated with a 
goat anti-rabbit secondary antibody conjugated with horseradish peroxidase (1:10000 
dilution; BioRad, Hercules CA) for 1 hr at 20°C. Following a final wash, membranes 
were developed with a chemiluminescent kit (Abersham ECL Plus Western Blotting 
Detection System; GE Healthcare, Piscataway NJ) and viewed using a film processor 
(Kodak X-OMAT film processor, Kodak Health Imaging Division, Rochester, NY). After 
developing, the membranes were striped and re-probed in order to measure the total 
amount of the protein of interest or α-tubulin in the cases of MuRF1, atrogin-1 and 
myostatin, where only total abundance of protein was measured. α-tubulin has been 
previously used in other studies of equine skeletal muscle to standardize protein 
abundance in Western blot analysis (211).  Band densities were determined using a 
densitometric computer software (ImageJ, National Institutes of Mental Health, Bethesda 
MD). The abundance of phosphorylated forms of Akt, S6K1, rps6, 4E-BP1, AMPK, NF-
κB and FoxO1 was corrected for the density of the total protein band and the value for 
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the control treatment was set at 1.0 arbitrary units. The abundance of MURF1, atrogin-1 
and myostatin were determined and compared to abundance of α-tubulin in order to 
correct for total protein. All gels were run in duplicate. 
4.2.5 Calculations.  
 
 Glucose infusion rate, in μmol/kg/min, was plotted against time so area under the 
curve (AUC) could be calculated using the trapezoidal rule (GraphPad Prism 4; 
GraphPad, La Jolla CA). Tissue sensitivity to exogenous insulin (M/I30) was calculated 
by dividing the rate of glucose infusion during the last 30 minutes (M) by the mean 
plasma insulin (I) during the last 30 minutes of the EHC procedure. Additionally, insulin 
sensitivity was assessed by the calculation of two proxies of insulin sensitivity that used 
baseline glucose and insulin concentrations: the reciprocal of the square root of insulin 
(RISQI) and the modified insulin-to-glucose ratio (MIRG), as previously described (96). 
4.2.6 Statistical analysis.  
 
Data was analyzed using a mixed procedure of SAS (version 9.3; SAS Institute 
Inc, Cary NC) with significance reported at P <0.05. Statistical trends were considered at 
0.05 < P <0.10.  
Measures of glucose metabolism and insulin sensitivity were analyzed using a 
one-way ANOVA with PPID status (group) as the fixed effect and horse nested in group 
as the random effect. Plasma glucose, insulin and amino acid concentrations were 
analyzed using repeated measures analysis with group, time and the interaction between 
group and time as the fixed effects and horse nested in group as the random effects. A 
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single baseline was determined by taking the average of the two baseline values for each 
variable. For each repeated measures analysis, the appropriate variance-covariance matrix 
was determined based on the lowest value for Schwarz Bayesian criterion. Basal and INS 
plasma glucose, insulin and amino acid concentrations at the time of biopsy and western 
blotting data were analyzed using a 2x2 factorial with group, insulin state (basal and INS) 
and the interaction between group and time as the fixed effects and horse nested in group 
as the random effects. All data are presented as least square means and pooled standard 
errors. 
4.3 RESULTS 
 
4.3.1 Plasma metabolite concentrations at the time of biopsy.  
 
Plasma glucose, insulin and indispensable amino acid concentrations were not 
affected by PPID status (P > 0.05) or the interaction between PPID status and insulin 
state (P > 0.05) (Table 4.1). Glucose concentrations were also not affected by insulin 
state (P > 0.05) (Table 4.1). Plasma insulin concentrations were significantly greater in 
the INS compared to the basal state (P < 0.05) (Table 4.1). Plasma isoleucine, leucine, 
methionine, threonine and valine concentrations were lower in the INS than in the basal 
state (P < 0.05), whereas the plasma concentrations of the other indispensible amino acids 
were not different between the basal and INS state (P > 0.05) (Table 4.1). 
4.3.2 Plasma metabolite concentrations during the EHC procedures.  
 
During the EHC procedures, there was an effect of time (P< 0.001) and an 
interaction between PPID status and time (P=0.04), but no effect of PPID status (P= 0.22) 
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on plasma insulin concentrations (Figure 4.1). Plasma insulin concentrations were 
increased ~9 fold at the time of the biopsy (t=120) when compared to baseline values. 
Despite the increase in plasma insulin concentration over the course of the procedure, 
plasma glucose concentrations were not different from baseline with the exception of a 
few transient changes, particularly immediately after the initiation of insulin infusion 
(Figure 4.1), consistent with the goal of the EHC procedure to maintain euglycemia. The 
PPID horses had a trend to have higher plasma glucose concentrations (P=0.07) during 
the EHC procedures compared to the CON group (Figure 4.1). There was a significant 
effect of time (P< 0.001), but no interaction between PPID status and time (P= 0.89) for 
plasma glucose concentrations during the EHC procedure (Figure 4.1).  
For all of the plasma amino acids studied, no interaction between PPID status and 
time (P> 0.05) was seen (Table 4.2). Plasma histidine and phenylalanine concentrations 
were not affected by PPID status or time (P> 0.05). Plasma isoleucine (P=0.002), leucine 
(P= 0.001), methionine (P= 0.01) and valine (P=0.04) concentrations decreased during 
the EHC procedures, but there was no effect of PPID status (P> 0.05). Plasma threonine 
(P= 0.01), lysine (P= 0.03) and tryptophan (P= 0.05) were all affected by PPID status, 
with higher concentrations seen in the PPID horses. Plasma threonine concentration was 
also affected by time (P= 0.05), but plasma lysine and tryptophan were not influenced by 
time of insulin infusion (P> 0.05). 
4.3.3 Measures of glucose infusion rate and insulin sensitivity.  
 
During the last 30 minutes of the EHC procedure, glucose infusion reached a 
plateau. At this time, the mean glucose infusion rate required to maintain euglycemia in 
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horses with PPID was similar to that of the CON horses (P=0.67) (Table 4.3) indicating 
no differences in insulin-dependent glucose disposal between the two groups. Further, 
there was no effect of PPID status on AUC for total glucose infusion (P=0.96), the M/I30 
ratio (P= 0.26), RISQI (P= 0.16) or MIRG (P= 0.61) indices (Table 4.3).  
4.3.4 Abundance of factors associated with protein synthesis and breakdown.  
 
 Representative blots for the proteins of interest are shown (Figure 4.2-4.5). No 
differences were found between the PPID and CON groups for any of the factors studied, 
nor were there any significant interactions between PPID status and insulin status (P> 
0.05). Insulin infusion significantly affected the phosphorylation of Akt (P< 0.001), rps6 
(P= 0.003) and 4E-BP1 (P= 0.003) in the gluteus medius muscle (Figure 4.2). The 
phosphorylation of NF-κB (Figure 4.3), AMPK (Figure 4.4), FoxO1 (Figure 4.5), and the 
abundance of myostatin (Figure 4.4), atrogin-1 (Figure 4.5), and MuRF1 (Figure 4.5) 
were not affected by insulin infusion (P> 0.05).  
4.4 DISCUSSION  
 
 Although insulin sensitivity in horses with PPID has been compared to younger 
controls (18, 19), to the authors’ knowledge, this is the first time that horses with PPID 
have been compared to age-matched, non-PPID controls using a dynamic test. The results 
of this study demonstrated that insulin sensitivity was not different between horses with 
PPID and CON horses using the EHC procedure and proxies, RISQI and MIRG, to 
measure insulin sensitivity (226). Further, this study marks for the first time that the 
abundance of many of these protein breakdown factors has been studied in equine 
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skeletal muscle. Increases in factors associated with protein synthesis were seen in 
response to insulin administration; however, no differences were seen between the PPID 
and CON groups for any of the protein synthesis and breakdown factors studied. 
Together these findings indicated that PPID status does not affect insulin sensitivity on a 
whole-body level or the ability of insulin to affect insulin-mediated signaling pathways at 
the muscle level. 
 The human form of Cushing’s disease is highly associated with insulin 
resistance, primarily due to high levels of circulating cortisol (226). Although horses with 
PPID generally have basal cortisol levels within the reference range (14, 15), it has been 
hypothesized that the cortisol circadian rhythm in horses with PPID may be abolished 
leading to increased cumulative cortisol over a 24-hour period (39), and ultimately 
insulin resistance in PPID horses. With the exception of slightly elevated plasma glucose 
concentrations during the EHC procedure, our study shows little evidence to support the 
hypothesis that the horses with PPID were more insulin resistant than CON horses. 
Initially, it was reported that measuring basal insulin had a high sensitivity in diagnosing 
PPID in horses (15); however, it does not appear to be specific indicator of PPID (227) as 
many non-PPID horses may also be hyperinsulinemic.  A large epidemiological study 
compared horses with PPID to aged controls and found that basal hyperinsulinemia 
occurred in 32% and 3% of horses, respectively. However, aged horses with PPID (~24 
years) were significantly older than the group of aged horses without PPID (~19 years) 
(1). Age is a factor that continually presents a problem when investigating the 
relationship between PPID and insulin sensitivity due to the nature of PPID affecting 
horses of advanced age. The results of this study suggest that age rather than PPID status 
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may be responsible for the decrease in insulin sensitivity that has previously been 
reported. 
It is likely that a decrease in insulin sensitivity occurs with advancing age. A 
study found that older horses (~27 yrs) needed nearly 200% and 150% more insulin to 
respond to an oral glucose tolerance test than young (~7 yrs) and middle-aged  (~15 yrs) 
mares, respectively (87). Further, a relationship has been found between age, 
inflammatory cytokines, and insulin sensitivity where older horses have increased 
inflammatory cytokine production and decreased insulin sensitivity (88). A weakness of 
the present study was that a control group of younger horses was not included in order to 
compare the insulin sensitivity of older horses with younger adult horses using the EHC. 
However, when the results of the present study are compared to another study done by 
our lab group using the same EHC procedure in younger adult horses (~8 yrs), the aged 
horses, both PPID and CON, showed ~75% decrease in rate of glucose infusion 
compared with the younger adult horses in the previous study (228). The RISQI and 
MIRG values for the PPID and CON horses can also be compared to the established 
references ranges defined by Treiber et al. (229) using a group of  healthy, mature horses 
(~9 – 18 years).  Using the established quintiles (229), the CON horses fell into the 3rd 
quintile and PPID horses fell into the 1
st
 quintile, with both groups in the bottom 50% of 
the established range for RISQI, a proxy measure for insulin sensitivity. Both groups fell 
into the 5
th
 quintile for the MIRG (229), indicating that while these horses were 
somewhat insulin resistant, they were able to compensate for this resistance with the 
increased β-cell release of insulin.     
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Alternatively, it is possible that insulin resistance may only affect horses with 
advanced PPID at a greater rate than aged-matched, non-PPID controls. Advanced PPID 
has been defined as those with hirsutism plus 3 or more clinical signs (1). Using this 
definition, only one PPID horse in the current group had clinical signs consistent with 
advanced PPID. This horse also had a basal insulin value of 34.1 μIU/ml, the highest of 
any horse included in this study and consistent with a diagnosis of hyperinsulinemia 
(230). All of the PPID horses included in the present study were relatively healthy and 
capable of being managed in a group setting due to the nature of maintaining an aged 
research herd. It is possible that if a greater number of horses with advanced PPID horses 
were included in the present study, differences may be have been detected between the 
PPID and CON groups. A study found that serum insulin concentrations were higher in 
PPID horses that did not survive the 1-2 year treatment period than in those horses that 
survived the entire study period (61).  This suggests that hyperinsulinemia and, thus 
insulin resistance, may be associated with end stage cases of PPID.  
Inflammation in the horse has been shown to increase with advancing age as part 
of a process known as inflamm-aging (218), leading to decreased insulin sensitivity (88) 
and increased protein breakdown (178). Interestingly, one study found that horses with 
PPID have decreased expression of several inflammatory cytokines when compared to 
healthy aged-matched controls that are similar to those of younger adult horses (219). In 
the present study, inflammation was not measured directly, but phosphorylation of NF-
κB is indicative of inflammatory status (179), with greater phosphorylation of NF-κB 
being suggestive of increased inflammatory signaling. No differences were found in the 
relative abundance of phosphorylated NF-κB between the PPID and CON groups in the 
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basal or insulin-stimulated state, thus it is unlikely that there was a difference in 
inflammatory signaling in the skeletal muscle between the two groups of aged horses in 
the current study. 
Insulin has the potential to affect protein synthesis through the activation of the 
mTOR signaling pathway, by phosphorylating Akt (119) . In the present study, no 
differences were seen between PPID and CON groups in phosphorylation of factors 
leading to protein synthesis, in either the basal of INS state. There were no differences 
between the PPID and CON horses in the plasma concentrations of glucose, insulin, or 
concentration of any of the amino acids at the time of either biopsy, which likely explains 
why no differences were seen in the activation of any of the mTOR signaling factors 
studied between these two groups of horses. However, the activation of both upstream 
factors, Akt, and downstream factors, rps6 and 4E-BP1, in the mTOR signaling pathway 
increased with the infusion of insulin by ~156%, 40% and 31%, respectively. The results 
of this study were consistent with a previous study that found insulin infusion increased 
the phosphorylation of factors associated with protein synthesis (Urschel et al., 
unpublished).  
At the time of biopsy, the plasma concentration of many of the indispensable 
amino acids were lower in the INS state than in the basal state, providing evidence that 
these amino acids were removed from the plasma and used in protein synthesis. A 
decrease in the concentration of the indispensible amino acids in the plasma is consistent 
with other studies using the EHC procedure in horses (Urschel et al., unpublished), 
humans (231) and pigs (232) . Although it is likely that the horses used in this study had 
decreased insulin sensitivity due to their advanced age, it appears they still had the ability 
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to respond to insulin with increased phosphorylation of factors associated with protein 
synthesis. It is important to note that the signaling factors studied are simply indicators of 
protein synthesis; however, studies in other species have shown that activation of mTOR 
signaling factors also coincided with an increase in muscle protein fractional synthesis 
rates (233). It is difficult to speculate if the aged horses had a decreased mTOR signaling 
response to insulin compared to younger horses, since a younger control group was not 
included in this study. However, in another study no differences were found in the 
phosphorylation of Akt, rps6 and 4E-BP1 between mature and aged horses in a post-
absorptive state (Wagner et al., in press), suggesting protein synthesis in the skeletal 
muscle in the horse may not be greatly affected by age specifically, although in the 
previous study differences between mature and aged horses were not determined in a 
stimulated (ie. post-feeding) state and therefore additional research is still needed. 
Myostatin acts as a negative regulator of skeletal muscle mass by inhibiting 
activation of Akt, mTOR and p70 S6 kinase 1 (155). In human studies of insulin 
resistance, plasma myostatin has been shown to be increased (234); however, no 
differences were seen in muscle abundance of this protein in the current study, which is 
consistent with previous studies of PPID horses compared to age matched controls (16). 
These results are in agreement with our conclusion that there is not an apparent difference 
in insulin sensitivity between PPID and CON horses. Another negative regulator of 
protein synthesis is AMPK, which is a sensor of cellular energy that is activated by rising 
AMP levels as a result of energy starvation and results in mTOR inhibition (220). AMPK 
may also have an important function in muscle wasting as it has been shown to increase 
the expression of MuRF1 and atrogin-1 (235). In the present study, no differences were 
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seen in phosphorylation of AMPK between the PPID and CON groups, indicating no 
differences in cellular energy status. 
Insulin mediates protein breakdown through the phosphorylation of Akt which 
has been demonstrated to phosphorylate and inactivate FoxO (203), leading to a decrease 
in protein breakdown. Muscle atrophy occurs when the rate of protein breakdown 
exceeds the rate of protein synthesis. Due to the muscle atrophy associated with PPID 
(16),  it would be expected to see an increase in factors associated with protein 
breakdown in the PPID compared to age-matched, non-PPID control horses; however, 
this was not observed in the present study. It has been proposed that major causes of 
muscle atrophy include insulin resistance and inflammation (178); however, it appears 
that there was no difference in insulin resistance and inflammation between horses with 
PPID and CON horses in the present study.  
In particular two genes, MuRF1 and atrogin-1 have been shown to have increased 
expression in multiple models of skeletal muscle atrophy, such as including diabetes, 
cancer, and adrenal failure (166). In the present study, no differences in MuRF1and 
atrogin-1 expression or phosphorylation of FoxO were seen between the two groups of 
aged horses, indicating no differences in skeletal muscle protein breakdown. Moreover, 
insulin infusion did not reduce the abundance or activation of any of the studied factors 
associated with protein breakdown. In a study using the EHC procedure in humans, a 
biopsy at 30 minutes into the insulin infusion revealed marked increases in 
phosphorylated FoxO expression (236), indicating that the 2 hour time period of insulin 
infusion should have been long enough to cause an increase in FoxO phosphorylation in 
the current study.  It is possible that because FoxO regulation of MuRF1 and atrogin-1 
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abundance occurs at the transcriptional level, that 2 hours may not have been sufficient to 
measure changes in the abundance of MuRF1 and atrogin-1. However, the lack of an 
effect of PPID or insulin status on MuRF1 and atrogin-1 is consistent with the lack of 
change in FoxO phosphorylation under these same conditions. It is known that insulin 
mediated signaling through the Akt pathway is non-linear (236), suggesting that even 
though Akt signaling had a normal response to insulin in the current study, it is possible 
that defects still exist insulin-dependent phosphorylation of factors downstream of Akt, 
such as FoxO . Therefore, the lack of insulin-mediated suppression of protein breakdown 
pathways provides some evidence that a portion of the muscle atrophy associated with 
old horses may be due to a decreased ability to suppress protein breakdown in response to 
anabolic stimulus. This is consistent with studies in rats and humans that have shown a 
decreased stimulatory effect of food intake on protein synthesis and its inhibitory effect 
on protein breakdown with old age (237, 238). The effect of aging on the balance 
between protein synthesis and breakdown pathways in the skeletal muscle of the horse is 
an area where additional research is warranted. 
It is still possible that there were differences in whole-body protein metabolism 
between the PPID and CON groups that were not captured by measuring the abundance 
or activation of the selected factors in the skeletal muscle. The horses with PPID had 
increased plasma concentrations of lysine, threonine and tryptophan when compared to 
the CON horses during the EHC procedures, indicating that there may be some 
differences in whole-body amino acid utilization between these two populations of aged 
horses. Plasma indispensable amino acid concentrations represent a balance between the 
processes that add and remove amino acids from the blood.  Both groups had similar 
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access to hay during the EHC procedure with minimal intake in both groups. Therefore, 
the other main mechanism where additional amino acids could have been added to the 
plasma would be through an increase in whole-body protein breakdown. Alternatively, 
elevated plasma amino acid concentrations could also indicate a reduction in amino acid 
use for protein synthesis in the PPID horses. A previous study in our laboratory utilized 
isotope infusion techniques in order to measure whole-body protein synthesis in horses 
with PPID compared to age-matched, non-PPID controls (Chapter III). The whole-body 
protein kinetics data provides no evidence that there were any differences in whole-body 
protein amino acid utilization between the PPID and age-matched, non-PPID control 
horses and therefore the cause of the differences in amino acid concentrations between 
the two groups of aged horses during the EHC procedures is an area that requires 
additional research. 
4.5 CONCLUSION 
 
 Although reduced insulin sensitivity is commonly associated with PPID, it had 
never been evaluated using a dynamic test comparing horses with PPID and CON horses. 
The results of this study indicate that reduced insulin sensitivity may occur as a normal 
part of aging, but is not directly associated with PPID status. Further, PPID status does 
not seem to alter the ability of insulin to affect insulin-mediated signaling pathways at the 
muscle level. The decrease in insulin sensitivity as seen in aged horses compared to their 
younger cohorts appears to be a multi-faceted condition with many other causes other 
than just PPID. Since all aged horses, regardless of PPID status, have the potential to be 
affected by reduced insulin sensitivity, it is important that all aged horses be monitored 
for potential problems associated with insulin resistance. 
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4.6 TABLES 
 
Table 4.1. Plasma glucose, insulin and indispensable amino acid concentrations at 
the time of biopsy collection in PPID and CON horses in the basal and insulin 
stimulated state
 1 
 CON   PPID   
 BASAL INS  BASAL INS Pooled SE  
Glucose
2 
4.37 4.64   4.90 5.37 0.36  
Insulin
3 
10.4 109.0*   16.0 136.4* 13.9  
Histidine
4 
45 41   48 43 5  
Isoleucine 60 40*   63 46* 5  
Leucine 101 65*   119 80* 12  
Lysine 71 66   85 77 7  
Methionine 33 22*   33 23* 4  
Phenylalanine 59 50   47 45 6  
Threonine 94 74*   110 91* 10  
Tryptophan 43 39   58 52 6  
Valine 190 138   231 166* 21  
 
1
Values are least square means, n=6/group, as determined using a 2x2 factorial with 
group, time (basal and EHC) and the interaction between group and time as the fixed 
effects and horse nested in group as the random effects. No differences were seen 
between group or an interaction between group and time. *Within a group, value differed 
significantly (P < 0.05) from baseline. 
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2
Plasma glucose concentrations are reported as least squares means in mmol/L 
3
Plasma insulin concentrations are reported as least squares means in µIU/mL. 
4
Plasma amino acid concentrations are reported as least squares means in µmol/L. 
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Table 4.2: Plasma indispensable amino acid concentrations (mmol/L) in CON and 
PPID horses in the basal and insulin stimulated state
1
 
 Group   p-values 
 CON PPID Pooled SE                    group time group*time 
Histidine  NS
2
 NS NS 
Baseline 42
 
56
 
5 
30 min 41 46 5 
120 min 40 43 5 
Isoleucine  NS 0.002 NS 
Baseline 53 65 4 
30 min 52 59 4 
120 min 40* 46
*
 4 
Leucine  NS 0.001 NS 
Baseline 86
 
122
 
11 
30 min 88 104 11 
120 min 65 80
*
 11 
Lysine  0.03 NS NS 
Baseline 71
a 
107
b 
9 
30 min 74 94 9 
120 min 66 77 9 
Methionine  NS 0.01 NS 
Baseline 26 30 3 
30 min 25 31 3 
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Table 4.2 continued: Plasma indispensable amino acid concentrations (mmol/L) in 
CON and PPID horses in the basal and insulin stimulated state 
120 min 22 23* 3 
Phenylalanine  NS NS NS 
Baseline 54 59 5 
30 min 54 58 5 
120 min 50 45 5 
Threonine  0.05 0.05 NS 
Baseline 88
a 
113
b 
9 
30 min 79 100 9 
120 min 74 91* 9 
Tryptophan  0.01 NS NS 
Baseline 39
a 
64
b 
5 
30 min 41
a 
56
b 
5 
120 min 39 52 5 
Valine  NS 0.04 NS 
Baseline 155 210 18 
30 min 158 190 18 
120 min 138 166* 18 
1
Values are least square means (in mol/L), n = 6/treament, as determined using a 
repeated measures analysis with compound symmetry used as the variance-covariance 
matrix.  
a,b
 Values with different subscripts differ significantly at the same time point. 
*Within a group, value differed significantly from baseline, P < 0.05. 
2
NS, not significant, P > 0.05 
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Table 4.3: Measures of glucose metabolism and insulin sensitivity for PPID (n=6) 
and CON groups (n=6) during the euglycemic hyperinsulinemic clamp procedures
1
 
 
 Group   
 CON PPID Pooled SE p-value 
RISQI (mIU/L)
-0.5
 0.34 0.27 0.03 NS
2
 
MIRG (mIUinsulin
2/[10∙L∙mgglucose]) 6.61 7.27 0.89 NS 
Glucose AUC ( mmol/kg)
3
 1239 1230 147 NS 
 M30 (mmol/kg/min)
4
 13.0 11.7 2.04 NS 
 M/I30 (mmol/kg/min per mIU/mL)
5 
0.129 0.094 0.022 NS 
1
All values are least square means, n=6/treatment. No differences were seen between the 
two groups (P > 0.05). 
2
NS= not significant, P > 0.05 
1
 Total glucose infusion during the clamp procedures. 
2 
Mean glucose infusion rate during the final 30 minutes of the clamp. 
3
 Tissue sensitivity to exogenous insulin. 
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4.7 FIGURES 
 
 
Figure 4.1. Plasma insulin concentrations (µIU/mL) in PPID (filled circle) and CON 
(open circle) and plasma glucose concentrations (mmol/L) in PPID (filled square) 
and CON (open square) during euglycemic hyperinsulinemic clamp procedures. 
Values are least square means ± pooled SE, n=6/group, determined by repeated measures 
analysis using the compound symmetry variance-covariance matrix for glucose and the 
autoregression heterogeneous variance-covariance matrix for insulin. Overall, insulin 
concentrations were effected by time (P< 0.001) and interaction between group and time 
(P= 0.04); however, there was no effect of PPID status (P=0.22) on plasma insulin 
concentrations during the EHC procedure. Plasma glucose concentration showed a trend 
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(P=0.07) to be higher in the PPID horses than in the CON horses. There was an effect of 
time (P< 0.001), but no interaction between treatment and time (P= 0.89). 
*Significantly different from baseline, P < 0.05. 
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Figure 4.2. Gluteal muscle phosphorylation of factors involved in the upregulation 
of protein synthesis, Akt at Ser
473
, rpS6 at Ser
235/236 & 240/244
, and 4E-BP1 at Thr 
37/46  
in CON and PPID horses during the basal (white bars) and insulin stimulated state 
(black bars). The phosphorylated forms of the translation initiation factors were 
corrected by the respective total form abundance, with the value for CON horses in the 
basal state set to 1.0 AU. Values are least square means ± pooled SE, n=6 per group. 
Representative images of the immunoblots are shown above. 
*
Values with significantly 
(P<0.05) different from baseline. 
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Figure 4.3. Gluteal muscle phosphorylation of NF-κB p65 at Ser536 in CON and 
PPID horses during the basal (white bars) and insulin stimulated state (black bars). 
The phosphorylated form of NF-κB was corrected by the respective total form 
abundance, with the value for CON horses in the basal state set to 1.0 AU. Values are 
least square means ± pooled SE, n=6 per group. Representative images of the 
immunoblots are shown above. 
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Figure 4.4. Gluteal muscle phosphorylation of negative regulators of protein 
synthesis, AMPKα at Thr172 and relative abundance of myostatin, in CON and PPID 
horses during the basal and insulin stimulated state. The phosphorylation of αAMPK 
was not affected by PPID status and did not differ between the basal (white) and insulin 
stimulated state (black). There was no interaction between PPID and insulin status. The 
phosphorylated form of αAMPK was corrected by the respective total form abundance, 
with the value for CON horses in the basal state set to 1.0 AU. Values are least square 
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means ± pooled SE, n=6 per group. Representative images of the immunoblots are shown 
above. 
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Figure 4.5. Gluteal muscle phosphorylation of FoxO1 and relative abundances of 
atrogin-1 and MuRF1, factors associated with protein degradation,
 
in CON and 
PPID horses during the basal (white bars) and insulin stimulated state (black bars). 
The phosphorylated form of FoxO1 was corrected by the respective total form abundance 
and atrogin-1 and MuRF1 abundances were normalized to total α-tubulin, with the value 
for CON horses in the basal state set to 1.0 AU. Values are least square means ± pooled 
SE, n=6 per group. Representative images of the immunoblots are shown above. 
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Chapter V 
 
Summary, General Discussion and Future Directions 
5.1 SUMMARY OF THE EFFECTS OF PPID ON THE AGED HORSE 
 
 The primary objective of this thesis was to determine the effects of PPID on 
protein metabolism (Chapter III) and insulin sensitivity (Chapter IV) in aged horses, with 
and without PPID.  The first study in this thesis (Chapter III) examined the effect of PPID 
on protein metabolism at the whole-body and skeletal muscle levels, by using isotope 
infusion techniques and analyzing specific factors associated with muscle protein 
synthesis and breakdown. The second study included in this thesis (Chapter IV) 
determined the effect of PPID on insulin sensitivity using euglycemic-hyperinsulinemic 
clamp techniques to measure insulin sensitivity at a whole-body level and further 
characterized insulin-mediated signaling by looking at factors associated with protein 
synthesis and breakdown. The results of these studies suggest: 
1. PPID does not significantly alter protein metabolism in the horse at the whole-
body or skeletal muscle levels. 
2. Aging may lead to a decrease in insulin sensitivity in all aged horses, not only 
those affected by PPID. 
3. PPID status does not significantly alter insulin sensitivity; however, some 
deregulations in glucose metabolism may exist in aged horses with PPID. 
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4. Aging may produce an abnormal response to feeding where amino acids to not 
reach the blood stream of the aged horse post-feeding to the same extent as in 
younger horses. 
5. Overall, the studies suggest that age rather than PPID status may be 
responsible for the abnormalities in muscle mass and insulin sensitivity that 
have previously been listed as characteristics of PPID. 
5.2 GENERAL DISCUSSIONS AND FUTURE DIRECTIONS CONCERNING 
RESEARCH OF PPID AND AGED HORSES. 
 
Although it is estimated that PPID affects 15-30% of aged horses (1, 2) , few 
studies have compared the clinical signs associated with PPID to age-matched controls. 
For most of the clinical signs associated with PPID the association is purely anecdotal 
based on observations from researchers and veterinarians; however, very few studies 
have actually compared these clinical signs to healthy aged horses, in order to understand 
the prevalence of these clinical signs in the normal aging horse population. Currently, the 
NRC does not make specific nutritional recommendations for aging horses, due to the 
lack of research in this field. However, it appears that physiologic differences, such as 
insulin resistance, may exist between the mature and aged horses making more research 
on aged horses needed. The research presented in this thesis did not look at the entire 
aging horse population, but instead chose to look at horses with PPID, a subset of the 
total population. Interestingly, the overall results from both studies showed very few 
differences between the two groups of aged horses.  
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When making comparisons to previous research in younger horses, it appears that 
some of the abnormalities seen in both studies may be a function of age rather than PPID 
status. Both studies presented in this thesis would have benefited from having a younger 
control group. The original objective of this research was to see how whole-body protein 
metabolism would differ between a population of horses that presumably had increased 
insulin resistance and increased muscle atrophy compared to the normal aging 
population. Initially, when making this comparison, it would seem that a younger control 
group was not necessary to complete the described objective. However, the differences 
between the two populations turned out to not be as distinct as previously suggested in 
the literature. 
Part of the discrepancy between the results of the studies presented in this thesis 
and previous research is likely due to age and the progressive nature of PPID. As 
previously mentioned, prior studies of insulin sensitivity in aged horses compared horses 
with PPID to a younger population of horses (18, 19). This was likely due to the nature of 
PPID affecting horses of advanced age, and lack of understanding of the decrease in 
insulin sensitivity associated with age. Further, accurately diagnosing PPID, particularly 
in the early stages, is difficult due to the low sensitivity of diagnostic tests. It is likely that 
in previous studies, advanced cases of PPID were chosen, since those were the horses 
visibly affected, making them easy to characterize as PPID.  
In the current research, the opposite problem may have occurred. This is to say 
that our study criteria likely selected for a healthier PPID horse. The horses included in 
this study were initially selected from a herd of 60 aged research horses. All of the horses 
in the herd were tested for plasma ACTH concentrations. Then, all horses with an ACTH 
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concentration greater than 50 pg/mL were given a dexamethasone suppression test to see 
if they would qualify for inclusion into the study. Using this method, some horses that did 
not stand out from the herd as being PPID based on appearance, since they did not 
present with substantial hirsutism, were included in the study.  Further, PPID is a 
progressive degenerative disease, and studies have shown that an increase in clinical 
signs occurs with increasing age (1). PPID also affects horses differently and a variety of 
clinical signs can be seen. To be included as part of the research herd at University of 
Kentucky’s Department of Veterinary Sciences, aged horses must be healthy and capable 
of being managed in a group setting. Due to these criteria, the PPID horses selected may 
have been atypical. For example, it has been demonstrated that horses with PPID have an 
increased predisposition for laminitis (41); however, if a horse in the research herd had 
chronic bouts of laminitis, it would likely be culled from the herd. Laminitis has been 
shown to be prevalent in horses with hyperinsulinemia or insulin resistance (22, 76); 
therefore, our herd may have been unknowing selected toward the healthier PPID horses, 
with clinical signs that do not require additional maintenance, and away from the 
extremely insulin resistant horse. 
Even if horses in the aged research herd were selected toward the healthier aged 
horse, it still doesn’t explain some of the unexpected findings that occurred in both 
groups of horses studied. Thus, additional research is needed in the aged population as a 
whole to explain some of the derailments in insulin-mediated glucose uptake and 
abnormal amino acid responses post-feeding.  Both groups of aged horses had a glucose 
infusion during the last 30 minutes of the EHC that was about 75% lower than horses (~8 
years old) in another study by our laboratory group (228). This observation suggests, that 
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age rather than PPID status may be responsible for the decreased insulin sensitivity that is 
seen in aged horses. Further, both the PPID and age-matched, non-PPID horses had an 
increase in glucose and insulin post-feeding as seen in previous studies. However, neither 
group had an increase in plasma amino acid concentrations post-feeding which suggests a 
potential decrease in amino acid digestibility or increased amino acid utilization by the 
splanchnic tissues. Previous studies have demonstrated that apparent crude protein 
digestion was reduced in aged horses (~25 yrs) when compared with younger horses (~2 
yrs) (195); however, the low protein digestibility seen in the aged horses was not 
observed in subsequent studies (196). However, the later studies did not include a 
younger control group, so it is difficult to speculate if differences in protein digestibility 
may have existed between the aged horses and younger controls. The current study 
suggests that this research needs to be revisited, as neither of the groups of aged horses 
included in this study showed the normal response to feeding of an increase in plasma 
amino acid concentrations. Further investigation of protein digestibility and absorption in 
the horse is warranted and may have important implications for the feeding of the senior 
equine. 
The studies included in this thesis leave many unanswered questions about PPID 
and the effects it may have on the aged horse. The problem with studies of PPID is the 
variety and severity of symptoms that may present in the horse. In future studies of PPID, 
it seems a larger population of PPID horses may be needed in order to better characterize 
a typical PPID horse. Further, it may be necessary to classify PPID horses as early stage 
or advance stage PPID, based on their clinical signs, in order to better characterize PPID 
horses. New research of PPID should focus on looking at improved diagnostic methods in 
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order to better diagnose early stage cases of PPID, which is currently limited by the 
available diagnostic methods. 
Ultimately, the research presented in this thesis suggests that horses with PPID 
and non-PPID aged horses may not have as many differences as initially believed. No 
differences were seen between the two groups of horses in insulin sensitivity or whole-
body protein metabolism. Further, no differences were seen between the PPID and age-
matched, non-PPID control groups in signaling factors associated with protein synthesis 
and breakdown pathways, nor did PPID status affect the ability of insulin to stimulate 
these pathways.  
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